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Abstract
Alzheimer’s Disease (AD) is characterized by Beta-Amyloid (Aβ) plaques within the brain.
Aβ peptides are produced by the cleavage of Amyloid Precursor Protein (APP).

Our

laboratory has previously discovered a novel pathway for APP internalization mediated by
ADP-ribosylation factor 6 (Arf6). This pathway resembles macropinocytosis, transporting
cell surface APP directly to lysosomes, a possible site for Aβ production. We set out to
characterize the effectors downstream of Arf6. In SN56 and N2A cells we co-transfected
HA-tagged APP (to label cell-surface APP) with compartment markers, to visualize APP
trafficking. We used dominant negative and constitutively active mutants, pharmacological
inhibitors, and siRNA for Rac1, Cdc42, and RhoA to determine their roles in APP
macropinocytosis. APP trafficking to lysosomes was reduced after knockdown of Rac1,
Cdc42, and RhoA, and inhibition of this transport reduced production of Aβ40 and Aβ42.
Our findings indicate a role for Rac1, Cdc42, and RhoA in Aβ production.
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Chapter 1: Introduction

1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. AD is a progressive,
neurodegenerative disease uniquely characterized by the deposition of beta-amyloid (Aβ)
plaques in the brain. AD’s main risk factor is age, with incidence rate increasing
substantially every 5 years starting at 65 years of age, with a 14 times higher occurrence
compared to those 85 and older (Hebert et al. 1995). Current estimates by the
Alzheimer’s Society of Canada suggest that roughly 600,000 Canadians have dementia,
and rising to over 1 million cases by 2038 (Smetanin et al. 2009). Global estimates either
mirror or are higher than the predicted Canadian estimates, with some continental regions
expecting a 5-times increased prevalence between 2006 to 2050 (Brookmeyer et al.
2007). With a quickly aging population, one of the greatest worries related to AD is the
heavy economic burden that will be placed on the healthcare system. With an estimated
cost of $15 billion according to a 2008 estimate and increasing to $160 billion by 2038
for Canada, AD will become one of the costliest and most challenging diseases in just a
few decades (Smetanin et al. 2009).

1.2 Beta-Amyloid
Alzheimer’s disease is characterized by synapse and neuronal loss, the appearance of
neurofibrillary tangles, and senile plaques in the brain. Of these characteristics, only the
development of senile plaques is unique to AD. Amyloid plaques are comprised mainly
of aggregates of beta-amyloid (Walsh et al. 2007; Wenk 2003). As a result of the strong
association between amyloid and Alzheimer’s disease, the current leading hypothesis for
the pathogenesis of Alzheimer’s disease is the amyloid hypothesis.
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1.2.1 Production of Aβ
Aβ peptides are produced from the sequential cleavage of the transmembrane protein,
amyloid precursor protein (APP). First, APP is cleaved at an extracellular β-site by a βsecretase. In neurons, this initial β-cleavage is the preferred pathway for the first step of
APP processing (Sinha et al. 1999). This secretase has been previously identified as an
endosomal transmembrane aspartic protease named beta-site APP-cleaving enzyme
(BACE) (Huse et al. 2000). The initial β-cleavage releases sAPPβ, a roughly 100 kDa, Nterminal soluble fragment, leaving a membrane bound 12 kDa C-terminal fragment
termed C99. Alternatively, APP can undergo α-cleavage instead through an α-secretase at
the plasma membrane to instead produce sAPPα, another large ~100 kDa N-terminal
soluble fragment, and C83, a 10 kDa C-terminal fragment (Thinakaran et al. 2008).
Further cleavage of the C83 fragment leads to a shortened 3 kDa fragment (p3),
containing only part of the Aβ sequence (Haass et al. 1993). As a result, α-cleavage of the
APP protein produces a non-pathological peptide, and the α-cleavage pathway is nonamyloidogenic. In the amyloidogenic pathway, which generates the toxic peptide
isomers, the C99 fragment remaining in the membrane is subsequently cleaved at a
variable γ-cleavage site by the presenilin protein. Presenilin is a part of the γ-secretase
complex, which has been shown to be active in a number of compartments such as the
endoplasmic reticulum and endosomes (Kimberly et al. 2000, Thinakaran et al. 2008).
This secondary cleavage of APP produces 36 to 43 amino acid long Aβ peptides and an
APP intracellular domain (AICD). The Aβ peptides generated in the greatest quantities
are Aβ40 and Aβ42. Of the two Aβ42 is generated in significantly lower quantities;
however, Aβ42 is more toxic and much more prone to aggregation and thus generates
amyloid plaques more easily (Iijima et al. 2008). These pathways are summarized in
Figure 1.

3

1.2.2 Amyloid Precursor Protein
Human APP is part of a family of Type-1 transmembrane glycoproteins including
amyloid precursor-like protein 1 (APLP1) and amyloid precursor-like protein 2 (APLP2),
in addition, the APP gene is located on chromosome 21 (Nicolas et al. 2014; Hardy et al.
2002). While APLP1 and APLP2 show functional redundancy with APP, neither of the
two has the Aβ sequence. APP is highly conserved, extending all the way down to
invertebrates such as Drosophila, in which the orthologue is β amyloid protein precursorlike (APPL) (Rosen et al. 1989). These proteins all exhibit a large extracellular Cdomain, and a short cytoplasmic N-domain. The APP gene itself can undergo alternative
splicing producing multiple different APP isoforms. The major APP mRNA species are
APP751, APP770, and APP695, with APP695 showing neuron-specific distribution and
APP751 and APP770 being expressed ubiquitously (Coburger et al. 2014).

1.2.2.1 Physiological Function of APP
The evolutionary conservation of APP and its homologues signify an important role in
normal physiology unrelated to the progression of Alzheimer’s disease. In mouse
embryos, APP was shown to increase in expression correlating with neuronal growth, and
to potentially be a marker for developing nuclei in the brain (Salbaum et al. 1994). While
some studies indicate it enhances neurite elongation, others suggest that it instead inhibits
elongation (Nicolas et al. 2014). Similarly, in the mouse fetal and postnatal brain, APP
was shown to be highly expressed in glial cells and neurons, especially during neuronal
differentiation (Trapp et al. 1994; Nicolas et al. 2014). While APP knockout mice show
no significant phenotype, APLP2/APLP1 or APLP2/APP double knockout mice were
non-viable, likely owing to the redundancy between the 3 similar proteins (Heber et al.
2000). In human embryonic stem cells, like in mice embryos, it has been shown that APP
is able to induce neural differentiation towards a neuronal phenotype (Freude et al. 2011).
Interestingly, APP interaction at synapses has been shown to regulate synaptic activity
(Wang et al. 2009). Unfortunately, despite all these possibilities there has still been no
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Figure 1. Pathways for APP processing. The Aβ domain is highlighted in red. The
amyloidogenic pathway is encompassed by a red box, while the non-amyloidogenic
pathway is enclosed by a green box. In the amyloidogenic pathway, the β-secretase first
cleaves APP on the endosomal membrane at the β-cleavage site producing sAPPβ and
C99. The C-terminal fragment C99 is then further cleaved by γ-secretase in an unknown
compartment to yield the 36-43 amino acid long Aβ peptide and the AICD. In the nonamyloidogenic pathway, α-secretase instead cleaves APP on the plasma membrane at the
α-cleavage site, in the middle of the Aβ domain, producing sAPPα and C83. Further γsecretase cleavage at an unknown compartment yields the non-toxic p3 and the AICD.
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definitive answer for the function of APP. The downstream products of APP may also
have their own physiological functions, such as AICD and soluble APP fragments,
sAPPα and sAPPβ, however their possible roles will be discussed further below.

1.2.2.2 APP in Alzheimer’s Disease
A number of mutations in the APP gene have been shown to be responsible for many
cases of Familial early onset Alzheimer’s Disease (FAD). These mutations are divided
into three classes and all these classes of mutations affect Aβ generation or deposition.
The first class of mutations is located near the β-cleavage site of APP. One notable
example from this class, the Swedish mutation, is located on the APP gene adjacent to the
location of the β-cleavage site, causing an increase in Aβ production by 10-fold (Mullan
et al. 1992). The second class, of mutations are located near the location of the γ-cleavage
site of APP, and increase the relative amount of Aβ42 thereby increasing the Aβ42/Aβ40
ratio. The London mutation is an example of a mutation belonging to this class (Goate et
al. 1991; Hendriks et al. 1992; Eckman et al. 1997). There are also mutations near the
alpha site that may decrease -cleavage or increase aggregation of Aβ. Some examples of
mutations from this class are the Arctic, Dutch, and Iowa mutations (Van Nostrand et al.
2001; Nilsberth et al. 2001; Cheng et al. 2004). Complete duplications of chromosome 21
in humans that houses the APP gene, which is observed in people with Down’s
syndrome, also results in AD pathogenesis much earlier in life (Cabrejo et al. 2006).
However, duplications of only the APP gene have been seen in rare families with FAD
(Rovelet-Lecrux et al. 2006; Sleegers et al. 2006). In summary, the main effect of APP in
Alzheimer’s disease is the generation of Aβ, and whether APP has other roles in
Alzheimer’s disease pathogenesis outside of this is not known.
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1.2.3 Normal Physiological Function of Aβ
The Aβ peptide was sequenced and identified as an Alzheimer’s disease marker more
than three decades ago (Glenner et al. 1984). Since then, Aβ has been studied extensively
with regards to its production in the hopes that halting this process could provide a
possible cure for Alzheimer’s disease. However, the physiological role of Aβ and its
purpose are still unclear.
The non-amyloidogenic route of APP processing produces sAPPα and C83 (See Figure
1). While not entirely understood, there have been numerous studies looking at the role of
sAPPα showing its ability to promote long-term potentiation (LTP), improve spatial
memory, as well as playing a role in neuroprotection (Taylor et al. 2008; Chasseigneaux
et al. 2012). It is also possible that sAPPα may play an antagonistic role to Aβ, providing
a possible neuroprotective effect (Hartl et al. 2013). Similarly, the role of C83 is not
known, however C83 is further cleaved to release p3 and an amyloid intracellular domain
(AICD). The role of p3 itself is not known, however AICD plays an important
transcriptional role. It has been found that AICDs associate with FE65, and the AICDFE65 bound complex must be liberated from APP through sequential cleavage before it
can translocate to the nucleus and bind to transcription factors there (McLoughlin et al.
2008).
In the amyloidogenic pathway, the first products are sAPPβ and C99. The two proteins
sAPPβ and sAPPα seemingly share identical functions; however, sAPPβ is 16 amino
acids shorter on the C-terminal. With regards to neuroprotective function and long-term
potentiation, sAPPβ has greatly reduced potency when compared to sAPPα (Barger et al.
1997; Taylor et al. 2008; Chasseigneaux et al. 2012). Therefore, it has been hypothesized
that the 16 amino acid C-terminal that is truncated during β-cleavage is highly involved
in both neuroprotection and LTP. As for C99, while a physiological role isn’t clear, a
transgenic

mouse

expressing

human

C99

was

shown

to

have

increased

acetylcholinesterase (AchE) activity in the medial septum of the brain, correlating with
poor spatial learning, as tested by a Morris water maze (Dumont et al. 2006).
Interestingly, it has been demonstrated that α-secretase has the ability to cleave C99,
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converting it to C83 and preventing further Aβ generation (Jäger et al. 2009). C99 is
further cleaved to produce Aβ and once again AICD, whose function has already been
discussed.
The normal function of Aβ is unknown. Aβ has been shown as having a possible
neuroprotective effect in neurons at very low doses (Kamenetz et al. 2003; Plant et al.
2003). Furthermore, this neuroprotective effect is based on Aβ peptide size, with some
studies showing that Aβ40 provides a neuroprotective effect in a concentration-dependent
manner, and other Aβ forms showing almost no effect. Furthermore, it has been
demonstrated that the Aβ peptide may be necessary for learning at physiologically low
doses (Morley et al. 2012). Puzzo et al. (2011) found that depletion of endogenous Aβ
impaired hippocampal LTP and learning, but injections of Aβ42 at picomolar
concentrations, similar to those normally present in the body, were able to rescue the
impairment in memory. Additionally, similar results were reported in another study, with
picomolar concentrations of Aβ improving memory (Morley et al. 2014). Aβ has also
been suggested to be able to regulate K+ and Ca2+ channel activity (Ramsden et al. 2002;
Plant et al. 2006), act as an antimicrobial peptide (Soscia et al. 2010), and regulate
cholesterol transport (Igbavboa et al. 2009; Yao et al. 2002). Contrary to the above
however, it has also been shown that higher levels of Aβ actually impairs memory and
cognitive function (Cleary et al. 2005; Ozdemir et al. 2013; Chambon et al. 2011). Aβ
has also been shown to stimulate synaptic depression, providing an additional role in
cognitive decline (Kamenetz et al. 2003). Furthermore, Aβ has been shown through
numerous studies to be toxic to synapses and neurons in AD (Walsh et al. 2007). These
studies provide a role for Aβ in the pathogenesis of Alzheimer’s Disease, which will be
discussed more fully below. However, despite all these possibilities there is no definitive
answer as to what role Aβ may play in normal physiology.
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1.2.4 Amyloid Beta and Alzheimer’s Disease
It has long been known that the Aβ peptide is the principal component of amyloid
plaques from previous studies looking at amyloid deposits in the brains of AD and
Down’s syndrome patients (Masters et al. 1985; Glenner et al. 1984). As mentioned
above, this link between AD and Down’s syndrome was solidified through studies that
showed pathological features in Down’s syndrome patients that were extremely similar to
those in AD, but at a much earlier age (Wisniewski et al. 1985). Specifically, Down’s
syndrome brains showed atrophy of the brain, as well as early growth arrest that is not
present in AD brains. Furthermore, localization of the APP gene points to chromosome
21, the chromosome that is duplicated in Down’s syndrome (Trisomy 21) (Tanzi et al.
1987). These results lead to the idea that increased APP expression, which would occur in
the case of an additional copy of chromosome 21, leads to increased Aβ deposits in the
brain, and prompted study into its neurotoxic effects. Another link between APP, Aβ and
Alzheimer’s disease came from studies done in FAD, which was already discussed
above. Further evidence came from β-secretase and γ-secretase themselves. β-secretase
has been shown to have both increased activity and protein expression in patients with
Alzheimer’s disease (Fukumoto et al. 2002; Holsinger et al. 2002). On the other hand, γsecretase mutations have been shown to be present in some FAD families, with
presenilin-1 (PS1) mutations comprising the largest group of FAD, but how these
presinilin-1 mutations affect γ-secretase activity is unknown. However, they appear to
cause Alzheimer’s disease by increasing the Aβ42/Aβ40 ratio (Tam et al. 2012). This can
occur through increased Aβ42 production in relation to Aβ40, or even decreasing Aβ40
production with no changes in Aβ42 production; some PS1 mutations even lower total
Aβ production, with a greater decrease in Aβ40 (Sheuner et al. 1996; Shimojo et al.
2007; Wolfe 2007).
Due to the strong association between Aβ and Alzheimer’s disease, much work has been
done to understand the pathological role that amyloid itself plays in neurodegeneration
and cognitive decline in AD. Of the two major Aβ forms, Aβ42 aggregates much more
easily than Aβ40. This was observed by Bitan et al (2003) where they observed
differences aggregation profiles. While Aβ40 was able to quickly form dimers, trimers,
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and tetramers, only Aβ42 aggregated to form large oligomers. Furthermore, the ratio of
Aβ42 to Aβ40 has been linked to the mean age of onset in Alzheimer’s disease patients
strengthening support for Aβ42 as the most toxic isoform (Duering et al. 2005). Aβ
oligomers themselves have been shown to disrupt synaptic plasticity, and inhibit longterm potentiation at physiologically relevant concentrations, contrary to what was stated
previously (Shankar et al. 2008; Walsh et al. 2002). The reason for the discrepancy
between these two lines of evidence is not clear, however a possible reason is stated in
the study by Walsh et al (2002), stating that Aβ oligomers are the cause for LTP
inhibition, not Aβ monomers. With the use of insulin-degrading enzyme (IDE), that only
degrades Aβ monomers and not oligomers, they were not able to prevent the inhibition of
LTP. Most importantly, Aβ oligomers are able to trigger synapse loss and neuronal death
(Deshpande 2006; Lambert et al. 1998; Shankar et al. 2007). However, another possible
pathological role for Aβ42 is in oxidative stress in the brain, contributing to neuronal
death (Weidner et al. 2011; Butterfield et al. 2002). Aβ is able to induce lipid
peroxidation impairing ion channels, glucose and glutamate transports, and guanosine
triphosphate (GTP) - binding proteins (Mattson 2004). This oxidative activity may occur
through the regulating aldehyde 4-hydroxynonenal (HNE) which conjugates to and alters
the activity of proteins (Mark et al. 1997). Aβ treatments in SK-N-BE cells have also
been shown to activate c-Jun amino terminal kinase (JNK) and p38 (MAPK), a pair of
stress-activated protein kinases that have been shown to demonstrate activity in neuronal
cells undergoing apoptosis (Tamagno et al. 2003).

1.2.5 Amyloid Cascade Hypothesis
Taken together, the foregoing findings provide a model for how Aβ may lead to the
synapse loss, neuronal death, and cognitive impairment characteristic of Alzheimer’s
disease, a pathway referred to as the amyloid cascade hypothesis. In this hypothesis it is
postulated that increasing relative Aβ42 generation, above natural levels of clearance in
the brain, will cause accumulation of Aβ and initiate Alzheimer’s disease pathogenesis.
In the original form of the Amyloid hypothesis, Aβ42’s ability to easily aggregate would
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result in rapid deposition occurs and plaque formation. Plaques were believed to alter
neuronal homeostasis and alter kinase and phosphatase activity, while promoting
generation of neurofibrillary tangles leading to the progression of dementia and
eventually, neuronal death (Hardy et al. 2002). However, there were a few problems that
the old amyloid cascade hypothesis was faced with. Of primary concern was that amyloid
plaque presence does not correlate well with cognitive function in humans, and similarly,
many mouse models with progressive Aβ deposition do not exhibit definitive neuronal
loss (Tam et al. 2012; Hardy et al. 2002). This point of contention may be explained
through the recent study of Amyloid Derived Diffusible Ligands (ADDLs), or large
soluble oligomers of Aβ. ADDLs have been shown to correlate well with synaptic loss
(Tomic et al. 2009), and may provide an explanation for why patients with Alzheimer’s
disease may show relatively little amyloid deposition. Furthermore, as discussed
previously, Aβ oligomers are orders of magnitude more toxic than the fibrils found in
plaques, inducing synapse loss and neuronal death at much lower concentrations (Walsh
et al. 2007).
The generation of neurofibrillary tangles (NFTs), composed of aggregated tau protein,
downstream of Aβ42 activity may serve to exacerbate this process further. NFTs are
present in other forms of dementia such as frontotemporal dementia. After suppression of
tau it has been shown that memory function recovers and fails to worsen further.
(Santacruz et al. 2005). Furthermore, it has been shown that Aβ42 is able to promote the
phosphorylation and aggregation of Tau, promoting Tau pathology, while Aβ40 actually
decreased Tau phosphorylation (Hu et al. 2014). This may reinforce the hypothesized
validity of the Aβ42/Aβ40 ratio by providing a mechanism for why having more Aβ40
relative to Aβ42 may be beneficial.

1.2.6 APP Trafficking
One important aspect of APP that regulates Aβ production is its trafficking. APP is
synthesized in the Rough Endoplasmic Reticulum (RER), exits its site of production, and
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is immediately transported to a number of locations intracellularly. The first site is the
Golgi, where APP undergoes post-translational modifications such as N- and Oglycosylation, phosphorylation, and tyrosine sulfation. While much APP at steady state
localizes to the Golgi and the trans-Golgi network (TGN), a major site of transport for
APP is the plasma membrane (Thinkaran et al. 2008). This is where α-cleavage of APP
may first occur, as well as the location where the adaptor protein FE65 can bind to the Cterminal end of APP (Sisodia 1992; McLoughlin et al. 2008). The binding of FE65 to a
YENPTY motif at the C-terminal of APP causes APP to be rapidly transported from the
plasma membrane back into the cell (Thinkaran et al. 2008). From here, APP moves back
into the cell through endocytosis towards the endosomal/lysosomal system which has
been shown to be necessary for Aβ production, as BACE1 and the γ-secretase complex
are localized to endosomes (Koo et al. 1994; Thinkaran et al. 2008). As further evidence
to the importance of APP internalization to Aβ production, it has also been found that
YENPTY mutations can inhibit APP internalization and decrease Aβ generation (Perez et
al. 1999). While much APP does localize to the Golgi/TGN, we have recently discovered
that APP is also able to traffic from the Golgi to lysosomes through adaptor protein 3
(AP-3), a lysosomal trafficking protein (Tam et al. 2014).

1.3 Endosomal/Lysosomal System
There

have

been

many

studies

done

suggesting

a

pivotal

role

for

the

endosomal/lysosomal system in the production of Aβ, where APP cleavage has been
shown to occur after endocytosis from the cell surface (Pasternak et al. 2004). Before
further discussing the role of the endosomal/lysosomal system in Aβ production, an
overview of system itself will first be provided (See Figure 2).
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Classical Endocytosis – Rab5 Dependant

1-10 minutes

Early Endosome
(Rab5)

Cell Surface

10-30 minutes

Late Endosome
(Rab9)
>60 minutes

Lysosome
(Lamp1)

minutes

Macropinocytosis – Arf6 Dependant

Figure 2. Routes for the internalization of APP to lysosomes. The best described pathway
of APP internalization occurs through classical clathrin-mediated endocytosis that occurs
through a Rab5-dependant mechanism. APP is first endocytosed into an early endosome,
which matures to a late endosome, before finally fusing with a lysosome. The entire
process from endocytosis to fusion with the lysosome can occur over hours. We have
discovered a second pathway for APP internalization we have found occurs through what
is believed to be macropinocytosis directly from the cell surface producing a
macropinosome that goes on to fuse with a lysosome. This process occurs very quickly
within minutes.
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1.3.1 Endosomes
Endosomes are small intracellular membrane-bound compartments that play a pivotal
role in the sorting and recycling of membrane components. This has effects on a number
of basic cellular processes, such as nutrient uptake, immunity, signaling, and
development (Scott et al. 2014). The materials within endosomes must first enter the cell
through a process named endocytosis. Endocytosis is defined as the internalization of the
plasma membrane, associated ligands, and the surrounding fluid (Hansen et al. 2009).
These endocytosed materials are commonly moved to an early endosome after
endocytosis from the cell membrane. Early endosomes serve as a sorting station, allowing
components that need to be moved to be recycled back to the plasma membrane,
transported towards the TGN, or transported towards lysosomes can all be separated
(Scott et al. 2014). Early endosomes (EE) eventually mature into late endosomes which
may transport endocytosed materials to the TGN or fuse with lysosomes. These two
major classes of endosomes, while serving a similar purpose, can be distinguished
between using the proteins they associate with. Early endosomes are closely associated
with the regulatory protein Rab5 along with its effector VPS34/p150, that generates
phosphatidylinositol 3-phosphate (PI(3)P). Rab5 also plays an important role later on as
the main regulator of conversion from early endosomes to late endosomes. Maturation of
early endosomes occurs through its recruitment of the protein Rab7 to the endosomal
membrane, which serves to exchange the fusion machinery of the maturing endosome to
ensure fusion of the late endosome only occurs with other late endosomes, lysosomes,
and the TGH (Huotari et al. 2011). Late endosomes are later strongly associated with
Rab9, a small GTPase that is essential for the retrograde pathway of transport from late
endosomes to the TGN, but not the anterograde pathway, from late endosomes to the
lysosome.
In summary, early endosomes and late endosomes can be differentiated between by
which Rab is presented at their membranes. Early endosomes present Rab5, while late
endosomes present Rab9 at their membranes. While Rab7 is also present at late
endosomes, as discussed above it is recruited to early endosomes as they mature into late
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endosomes as well, so for the purposes of differentiation, Rab9 is a better marker (Lu et
al. 2014). Late and early endosomes may also be differentiated by their lumenal pH.
Early endosomes typically have a pH ranging from 6.8 to 6.1, while late endosomes show
a pH in the range of 6.0 to 4.8. This distinguishes them from lysosomes, which can have
pH values as low as 4.5 (Maxfield et al. 1987). This lowered lumenal pH serves multiple
purposes in the endosomal system such as inactivation of pathogens, in membrane
trafficking, and the further sorting of cargo. The lowered pH also serves as a better
environment to better facilitate ligand-receptor dissociation on the membrane, allowing
receptors to be recycled back to the plasma membrane (Huotari et al. 2011). Another
marker of late endosomes is Mannose-6-phosphate receptors (M6PR). M6PR traffics
between the late endosome and the TGN through the packing of lysosomal hydrolases
tagged with M6P facilitated by binding to the M6PR. The hydrolases are then transported
to the late endosomes where the lumenal pH causes dissociation between M6P and the
M6PR. The M6PR is then recycled to the TGN to once again bind M6P (Lu et al. 2014).

1.3.2 Lysosomes
In the 1950s lysosomes were described as the major digestive compartment of cells by
Christian de Duve and his group (Appelmans et al. 1955; de Duve 2005). From studies
performed in rat livers he suggested the existence of a membrane-bound compartment
with a low pH containing a number of hydrolytic enzymes, dubbing it the lysosome (de
Duve 2005). Since then, lysosomes have been considered to be the garbage cans of the
cell, simply a place for damaged proteins, unneeded signaling molecules, and other
cellular parts to go for breakdown and eventually recycling of their materials. However,
as more research into lysosomes occurs it has been revealed that lysosomes are necessary
for many cellular processes important to homeostasis aside from degradation such as
plasma membrane repair, cholesterol homeostasis, and the regulation of apoptosis. The
importance of the lysosome to homeostasis is also highlighted by the fact that there are a
group of over 40 diseases related to the lysosome, referred to as lysosomal storage
diseases. These diseases occur through the accumulation of metabolic end products
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within the lysosome as a result of either missing or impaired function of lysosomal
enzymes (Pasternak et al. 2004). In terms of diseases related to lysosomal trafficking,
there exists at least one example, a rare condition called Chédiak-Higashi syndrome. In
this extremely rare disease, a mutation in the LYST protein, a regulator of lysosomal
trafficking, results in enlarged lysosomes and heavily impaired immune function (Kaplan
et al. 2008).
Material for degradation in the lysosomes arrives through multiple pathways. The first
pathway, endocytosis, sees the fusion of a late endosome with a lysosome to form a
secondary lysosome, which then fuses with more lysosomes later. Late endosomes
targeted for the lysosomal degradation pathway and lysosomes themselves are enriched
in marker Rab7 (but not Rab9 like in late endosomal transport to the TGN) and the
lysosomal-associated membrane protein 1 (LAMP-1), a transmembrane protein showing
high expression in lysosomes. Lysosomes also lack the mannose-6-phosphate receptor
(M6PR), which is present in late endosomes (Appelqvist et al. 2013). As discussed
above, the pH of late endosomes is quite low, and decreases as it fuses with lysosomes,
eventually reaching standard lysosome pH of 4.5. This decrease in pH is facilitated by
ATP dependent proton pumps (Vacuolar ATPases) on the membrane that lower lumenal
pH of the vesicles. This low pH is necessary for the hydrolytic function of the proteases
within the lysosome, which function optimally in highly acidic environments (Appelmans
et al. 1955; Coffey et al. 1968). The second pathway, autophagy, transports cytoplasmic
proteins, whole organelles, cytoplasm, and anything within the cytoplasm directly to
lysosomes for degradation. In immune cells, phagocytosis and macropinocytosis also
transport extracellular material to the lysosome for degradation. The entire process from
early endosome formation to lysosomal fusion takes approximately 40 minutes
(Appelqvist et al. 2013). The process of degradation in the lysosome is achieved by ~60
different hydrolases. These hydrolases include proteases, peptidases, phosphatases,
nucleases, glycosidases, sulfatases, and lipases. Of these hydrolases some of the best
known ones are from the cathepsin family, being divided into three different groups
based on the active site amino acid. These are serine (including cathepsin A and G),
aspartic acid (cathepsin D and E), and cysteine (cathepsins B, C, F, H, K, L, O, S, V, W
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and X). Of the above, the most abundant and ubiquitous of the cathepsins in lysosomes
are: cathepsin B, C, D, H, and L (Rossi et al. 2004).
More recently, lysosomes were demonstrated to have secretory function as well,
dispelling the myth that lysosomes only served as the endpoint for endocytosed materials.
In a study conducted by Rodriguez et al (1997) it was found that lysosomes were able to
secrete calcium in both fibroblasts and epithelial cells, not just specialized secretory cells,
in response to high intracellular calcium. This lysosomal secretion appears to be
regulated by the GTPase, Rab27, which has two isoforms, shown to regulate exocytosis
of lysosome-related organelles in a number of cells (Izumi et al. 2003; Izumi 2007). From
there the lysosome fuses with the membrane, releasing its contents extracellularly
(Jaiswal et al. 2002). This recent change in the understanding of lysosomes has revealed
several pivotal roles for lysosome secretion. In osteoclasts there is evidence suggesting
that lysosomes through exocytosis are able to transport vacuolar type H +-ATPase (VATPase) to the plasma membrane. Once there, V-ATPase causes extracellular
acidification, mobilizing bone calcium (Toyomura et al. 2003). Lysosomes also play a
role in cell membrane repair, as Reddy et al (2001) showed that elevation of intracellular
calcium, which would occur in plasma membrane damage, is required for lysosome
exocytosis, further demonstrated in the resealing of primary skin fibroblasts through
lysosomal exocytosis. This corroborates the work done earlier by Rodriguez et al
discussed previously, showing that that high intracellular calcium stimulated lysosome
secretion. Additionally, lysosome exocytosis has been shown to also regulate ATP
release in astrocytes, with ablation of ATP secretion occurring after lysis of lysosomes
(Zhang et al. 2007). Lysosomal secretion may also be vital in the presentation of MHC
Class II-antigen complexes at the plasma membrane (Andrews 2000).

1.3.2.1 Lysosomes and Alzheimer’s Disease
As the roles of lysosomes in the cell and as a regulator of normal physiology expand an
increasingly large number of diseases have been linked to lysosomal dysfunction. A
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number of studies in Alzheimer’s disease have noted a connection between AD and
altered lysosomal function, as well as Aβ production (Nixon et al. 2011; Lee et al. 2010;
Coen et al. 2012). Starting with the internalization of APP, studies have shown for a long
time that that Aβ generation requires the normal functioning of endocytosis (Cirrito et al.
2008; Koo et al. 1994). Furthermore, de-acidification of this system causes significant
reductions in the production of Aβ, as shown through the application of the alkalizing
agents ammonium chloride (NH4Cl), bafilomycin A1 (bafA1), chloroquine, and
concanamycin A (Schrader-Fischer et al. 1996; Vingtdeux et al. 2007). The previous
study mentioned by Schrader-Fischer and Paganetti (1996) showed the accumulation of
APP intracellularly after the application of alkalizing agents. However, C-terminal
generation of the C99 was completely inhibited. As C99 is generated through the initial
β-cleavage of APP it is possible that de-acidification of endosomes may halt APP
generation at the β-cleavage step. However, APP processing inhibition from deacidification may also occur at the γ-cleavage step.
We have found previously that nicastrin, a major lysosomal membrane protein, APP and
presenilin-1 all colocalize strongly with LAMP1. Additionally, in the same study γsecretase demonstrated optimal activity in highly acidic environments, similar to what
would be present in the lysosome (Pasternak et al. 2003). As further evidence for
lysosomes as the location of γ-secretase activity, in PS1(-/-) murine neurons, the COOHterminal fragment (CTF) which is eventually cleaved by γ-secretase also showed
accumulation in the lysosomes as a result of loss of function in PS1 (Chen et al. 2000).
Lastly, a number of studies have shown that Aβ is secreted in exosomes, which are
intraluminal vesicles of the late endosome/lysosome (Rajendran et al. 2006; Vingtdeux et
al. 2007).
Apart from Aβ generation, it has also been suggested that lysosomes may also play a role
in the aggregation of Aβ to form the fibrils present in amyloid plaques. It has been known
for over a decade that Aβ fibrillogenesis occurs optimally at acidic pH levels, a wellknown characteristic of the lysosome; even at mild pH levels, like those seen in
endosomes, Aβ aggregates begin to form, albeit to a lesser degree than at a lower pH (Su
et al. 2001; Inouye et al. 2000; Gorman et al. 2003). In addition, gangliosides present in
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the plasma membrane of lysosomes in tandem with a low pH have also been shown to
accelerate Aβ aggregation, as well as promote membrane disruption (McLaurin et al.
1996; Waschuk et al. 2001). Aggregation of Aβ has even been shown to occur upon the
application of exogenous Aβ42, with markers pointing to the late endosome or lysosome
as one of the major sites of accumulation and aggregation (Burdick et al. 1997; Knauer et
al. 1992). Aβ fibrils themselves have demonstrated the ability to disrupt lipid membranes
at synapses and in lysosomes, initiating leakage of lysosomal contents resulting in cell
death (McLaurin et al. 1996; Yang et al. 1998; Ji et al. 2002). The connection between
lysosomal leakage and cell death may come from either apoptosis initiated by activation
of caspase proteases, from the release of lysosomal hydrolases into the cell, or from the
liberated Aβ itself (Zhang et al. 2007).
Despite all the evidence provided, lysosomes have yet to be confirmed as the definitive
site for Aβ production in Alzheimer’s disease. The Golgi, plasma membrane, and ER
have also been suggested as possible sites by other authors. However, the lysosome still
provides possibly the best location for a major site of Aβ production, and so we believe
that by studying the pathways that transport APP to the lysosome we may be able to
eventually find therapies that work for Alzheimer’s disease. For example, since APP is
required to undergo endocytosis for the generation of Aβ it may be possible to inhibit
APP trafficking at this first step, thereby eliminating the progression of the amyloid
cascade and providing a future avenue for therapy in Alzheimer’s disease patients.

1.4 Endocytosis
Endocytosis can be divided into two basic categories, clathrin-dependent endocytosis, or
clathrin-mediated endocytosis (CME), and clathrin-independent endocytosis (CIE).
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1.4.1 Clathrin-mediated endocytosis
Clathrin-dependent endocytosis, also referred to as classical endocytosis, is the best
understood process. Clathrin-dependent endocytosis generates small (~50 nm - ~100 nm
diameter) vesicles coated with the protein clathrin from which this process derives its
name. The first step of clathrin-mediated endocytosis is assembly of clathrin into a
polygonal lattice and the formation of coated pits on the plasma membrane that is
promoted by adapter protein-2 (AP-2) (Merrifield et al. 2014). In these coated pits,
clathrin assembles into a shape referred to as a triskelion, reminiscent of a spiral with 3
arms. This assemblage consists of three heavy and three light clathrin chains bound
together. The clathrin heavy chain has been suggested to be important for binding to AP2, while the light chain has been suggested to regulate the actual formation of the clathrin
assembly (Mousavi et al. 2004). AP-2, along with other adapter proteins, binds the
cytosolic tails of membrane proteins, and is essential for localization of the clathrin onto
the plasma membrane. More specifically, AP-2 binds phosphatidylinositol-4, 5bisphosphate (PIP2), an important signaling molecule for multiple modes of endocytosis,
causing a conformational change to reveal cargo and clathrin-binding motifs. When the
AP-2 complex then successfully binds receptor cargo and clathrin, nucleation of a
clathrin-coated pit is initiated (Jackson et al. 2010). The clathrin-coated pits invaginate
further until only a “neck” remains connecting a fully enclosed clathrin-coated vesicle.
This neck is then severed by a large GTPase named dynamin thereby releasing the
clathrin-coated vesicle from the plasma membrane (Merrifield et al. 2014). At this point
vesicles are able to fuse with early endosomes and thought to be sorted for recycling or
trafficking to late endosomes as previously discussed. The fate of the vesicle after this is
movement to the lysosome of TGN. Generally, the entire process for transport to
lysosomes or the TGN may take up to an hour, with proteins showing in early endosomes
as early as 10 minutes, and in late endosomes as early as 30 minutes.
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1.4.2 Clathrin-independent endocytosis
The clathrin-independent class of endocytosis encompasses multiple different pathways.
These pathways are macropinocytosis and endocytosis, for large vesicles (>1 μm), and
the caveolar, flotillin, and CLIC/GEEC pathways for smaller vesicle sizes. The
microscale pathways for clathrin-independent endocytosis will be discussed here, while
phagocytosis and macropinocytosis will be discussed further on.

1.4.2.1 Caveolar Pathway
Of the dynamin-dependent pathways of CIE, the caveolar one is the best studied.
Caveolae are 50-80 nm wide, flask-shaped plasma membrane invaginations rich in
caveolin, as its name suggests. In addition to caveolin, caveolae are enriched in
sphingolipids,

cholesterol,

signaling

proteins,

and

clustered

glycosyl

phosphatidylinositol-anchored proteins (GPI-Aps). The caveolins were first discovered
with the identification of caveolin-1 (CAV1) over two decades ago, after which caveolin2 (CAV2) and caveolin-3 (CAV3) were also identified (Rothberg et al. 1992). CAV1 and
CAV2 are only present in non-muscle cells, whereas CAV3 localizes to skeletal muscle
and to a limited degree in smooth muscle cells (Parton et al. 2007). CAV1 and CAV3
ablation causes the loss of caveolae, while no similar effect is seen with CAV2 ablation.
Although it is possible that because CAV1 and CAV2 are present in the same types that
there is redundancy between the two proteins (Drab et al. 2001; Galbiati et al. 2001;
Razani et al. 2002). Caveolae form through the oligomerization and association of
caveolin with cholesterol-rich lipid-raft domains. As a result of the tight association
between the caveolin protein and cholesterol, cholesterol depletion has been shown to
cause the disassembly of caveolae (Rothberg et al. 1992). Endocytosis of caveolae
waiting at the plasma membrane is initiated by a number of different ligands ranging
from albumin, to viruses, and even sterols and glycosphingolipids (Pelkmans et al. 2002;
Sharma et al. 2004; Minshall et al. 2002). Budding of the caveolae itself is regulated by
the Src-family kinases, local actin polymerization, and dynamin, hence its classification
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under dynamin-dependent CIE (Sverdlov et al. 2007). Unfortunately, study of caveolar
mechanisms as well as those in dynamin-dependent, caveolin-independent pathways has
been made difficult by a number of problems. First, endocytic cargo that travels through
caveolin-dependent pathways can also be internalized through different mechanisms in
other cell types, or even the same cell itself. Secondly, other lipid-raft endocytosis
pathways that are clathrin- and caveolin- independent have been discovered, confounding
the study of other clathrin-independent forms of endocytosis (Mayor et al. 2007).

1.4.2.2 Flotillin Pathway
The flotillin-dependent was first suggested after the observation of residual caveolar
structures despite caveolin-1 depletion in mice models for knockout of the caveolin-1
gene (Zhao et al. 2002). It was not until later that flotillin 1 and 2, proteins that are
associated with the membrane in caveolae, were observed to generate caveolar-like
structures independent of both caveolin and clathrin (Glebov et al. 2006; Frick et al.
2007). However, in mouse embryonic fibroblasts with a knockout for caveolin-1, but also
overexpressing flotillin 1 and 2, caveolae were not generated (Kirkham et al. 2008).
Therefore, the flotillin-mediated pathway is not currently a definitive pathway for CIE.

1.4.2.3 CLIC/GEEC Pathway
The best-described clathrin-independent, dynamin-independent pathway is the clathrinindependent carriers/ GPI-AP enriched early endosomal compartments (CLIC/GEEC)
pathway. The carrier for this pathway is a 100-200 nm large ring-shaped compartment
(Kirkham et al. 2005). This pathway was first identified in a study of HeLa cells in which
impairment of dynamin-1 increased fluid-phase uptake through a clathrin-independent
pathway (Damke et al. 1995). The implication of Cdc42 in this pathway was later
discovered in a study following the internalization of glycosylphosphatidylinositol-
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anchored proteins (GPI-APs). In this study no change was observed in GPI-AP
endocytosis after RhoA, dynamin 2, or Rac1 inhibition. However, Cdc42 inhibition was
able to diminish fluid-phase uptake and redistribute GPI-APs to clathrin-mediated
endocytosis (Sabharanjak et al. 2002). This pathway has been shown to also be the main
endocytic route for cholera toxin B, Helicobacter pylori vacuolating toxin, and the GPIanchored cellular prion protein (PrPC) (Mayor et al. 2007). Additionally, Arf1 has been
shown to also be involved in regulation of this pathway, and because of the substantial
involvement of Arf1 and Cdc42 it has been suggested that this pathway may also be
regulated through other key proteins in actin dynamics (Kumari et al. 2008).

1.4.3 Macroscale Endocytosis

1.4.3.1 Phagocytosis
Phagocytosis was initially discovered by Metchnikoff over 100 years ago (Flannagan et
al. 2012). Since then, numerous roles for phagocytosis have been uncovered aside from
the adaptive immune response to pathogens; this includes tissue homeostasis and
remodeling. Phagocytosis is by definition the ingestion of particles greater than 0.5 μm in
diameter. Phagocytosis differs from the other form of macroscale endocytosis
(macropinocytosis) because it is directed through cell surface binding directly to target
particles or foreign bodies causing projections to protrude from the membrane, encircling
and engulfing the foreign object. After total enclosure of the object and scission from the
membrane the compartment is called a phagosome. The phagosome then moves
intracellularly, fusing with a lysosome to degrade the lumenal contents of the phagosome.
Through this they have well-documented roles in immune defense, and even the ingestion
of apoptotic bodies in non-immune cells (Flannagan et al. 2012). As phagocytosis
functions in such a broad role, there are many receptors that have been found and studied
in the initiation of phagocytosis.
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Phagocytosis is triggered by receptor binding at the cell surface. Most of these receptors
can be separated into three main categories: Fc receptors, integrins, and a very diverse
third group, the pattern-recognition receptors which are not well understood but include
Dectin-1 receptors and scavenger receptors (Freeman et al. 2014).
The first group, the Fc receptors, facilitate phagocytosis through the binding of
opsonized-immunoglobulin G (IgG) particles (Indik et al. 1991), and provides a
mechanism for clearing antibody-bound pathogens/targets. There are six different human
Fc receptors (FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA, and FcγRIIIB) that have the
ability to bind to multiple different IgGs with differing affinities for each (Bruhns et al.
2009). Once bound to immunoglobulin, Fc receptors initiate phagocytosis through actin
polymerization at the plasma membrane. Actin polymerization is facilitated by
recruitment of the Arp2/3 complex to the phagocytic cup. The Arp2/3 complex is
normally inactivated and must be activated by neural Wiskott-Aldrich syndrome protein
(N-WASp) in order for actin nucleation to begin (Park et al. 2009; Lorenzi et al. 2000;
Tsuboi et al. 2007). However, N-WASp must also be activated itself before it can
activate bind and activate the Arp2/3 complex. This is achieved through the binding of
the small GTPase, Cdc42, as well as phosphatidylinositol 4,5-bisphosphate (PIP2), a
small phospholipid which is an important molecule in many types of endocytosis as
mentioned previously (Prehoda et al. 2000). Other actin dynamic regulators that have
been shown to play a role are Rac1 and Rac2, Arf6, and even RhoA (Hoppe et al. 2004;
Hall et al. 2006; Zhang et al. 1998; Jankowski et al. 2008; Beemiller et al. 2006).
Interestingly, the WASP family Verprolin-homologus (WAVE) complex, which performs
a similar role to N-WASp in the activation of the Arp2/3 complex and initiation of actin
nucleation, has been shown to not be necessary for Fc receptor-mediated phagocytosis
(Kheir et al. 2005). To add to this, the WAVE complex is activated downstream of both
Rac1 and Arf6 as well. However, despite linking the proteins above to FcγR-mediated
phagocytosis, their exact role and their effectors in this process are unknown. After
engulfing the IgG-bound particle actin polymerization is halted through currently
unknown means, although some studies suggest phosphatidylinositol 3-kinase (PI3K)
may regulate this process (Freeman et al. 2014). The compartment that is released from
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the membrane is called a phagosome, eventually fusing with a lysosome to degrade the
contents within.
The second group of receptors, the integrin receptors, facilitates the second most studied
pathway, complement-mediated phagocytosis. Integrins, which are cell adhesion
molecules, have the ability to dynamically change their adhesion based on a process
called inside-out signaling or priming, allowing binding of ligands to be enhanced as they
contact more receptors (Luo et al. 2007). CR3, also known as αMβ2 integrin or Mac-1, is
the most well-known receptor. This receptor is known to have the capability of binding
30 different ligands, being able to bind both opsonized and un-opsonized targets (Le
Cabec et al. 2002). CR3-mediated phagocytosis requires the GTPases RhoA and Rap1.
RhoA in this process recruits mDia formins, a group of Rho family effectors that cause
actin to undergo nucleation, which initiate formin-dependent actin polymerization, a
process that is regulated by profilin, which is recruited by Rap1 (Kim et al. 2012;
Romero et al. 2004; Barry et al. 1997; Hall et al. 2006). RhoA also activates Rho kinase
to phosphorylate the light chain of myosin II, helping to force the actin extensions
outwards (Olazabal et al. 2002). Rap also regulates cofilin, an actin depolymerization
protein that serves to regulate the magnitude of the receptor response in CR3-mediated
phagocytosis (Freeman et al. 2011). Rac1 and Rac2 have also been shown to play a role
in this pathway, however their exact role isn’t clear (Hall et al. 2006). Similar to FcγRmediated phagocytosis, the process that halts actin polymerization hasn’t been identified;
however, PI3K is once again suggested to regulate this process. At this point
phagocytosis proceeds similarly and once again fuses with lysosomes to degrade the
contents of the phagosome.

1.4.3.2 Macropinocytosis
The other form of macroscale endocytosis, and the one most relevant to this study is
macropinocytosis. Macropinocytosis is a highly regulated and conserved mechanism for
the bulk, non-selective uptake of extracellular fluid. First discovered in 1931,
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macropinosomes were first observed to be large (>0.2 μm) vesicles produced by sheetlike extensions of the plasma membrane, which are called ruffles (Kerr et al. 2009).
Unlike phagocytosis, macropinocytosis is thought to occurring spontaneously or by
stimulation by growth factor receptors. Macropinocytosis begins with ruffles formed at
the plasma membrane, which usually retract back into the cell; however, some may fold
back and fuse with the membrane enveloping extracellular media, forming
macropinosomes. The macropinosomes eventually fuse with lysosomes as they mature,
or recycle back to the plasma membrane (Kerr et al. 2009). Macropinocytosis has major
functions in antigen presentation and pathogen entry, and may be important in cell
motility (Lim et al. 2011). In neutrophils, macropinocytosis has been shown to be
important for complement receptor-1 (CR1) internalization. CR1 is an example of a
number of receptors important to the chemotactic response in neutrophils (Carpentier et
al. 1991).
Macropinosomes

exhibit

many

characteristics

similar

to

vesicles

in

the

endosomal/lysosomal and phagolysosomal systems. In macrophages, macropinosomes
have been found to be able to acquire makers of late endosomes, such as Rab7, before
finally fusing with lysosomes (Racoosin et al. 1993). It has been found that sorting nexin
5 (SNX5) is also recruited to newly formed macropinosomes before fusing with
lysosomes (Lim et al. 2008; Kerr et al. 2006).
Like the formation of phagocytic cups, membrane ruffle growth is generated through the
protrusion of actin extensions from the membrane, facilitated by actin reorganization and
polymerization at the plasma membrane, so proteins that regulate actin dynamics are
highly important to macropinocytosis. The Ras superfamily of proteins has a number of
members which are necessary for the formation of the macropinosomes, such as Ras,
RhoG, and most importantly, Arf6 and the Rho GTPases, Rac1, Cdc42, and RhoA
(Swanson 2008). Many of these proteins will be outlined in further detail below,
however, their main purpose in actin reorganization is to activate the WASp and WAVE
complexes. As previously discussed, these complexes bind to Arp2/3, as well as PIP2, an
important signaling molecule in multiple forms of endocytosis that is generated from the
phosphorylation of phosphatidylinositol 4-phosphate (PI(4)P) by phosphatidylinositol 4-
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phosphate 5-kinase (PIP5K). This double binding activates Arp2/3 initiating actin
nucleation through the direct assembly of an actin monomer onto an existing actin
filament (Kerr et al. 2009). The proteins p21-activated kinase-1 (Pak1) and CtBP1/BARS
are also highly involved, with their purpose being closure and scission of the
macropinosome (Liberali et al. 2008; Edwards et al. 1999). Figure 3 summarizes some of
the pathways involved in macropinocytosis above which will be further discussed below.

1.5 Macropinocytic Regulation

1.5.1 ADP-ribosylation Factor 6
ADP-ribosylation Factor 6 (Arf6) is a small GTPase that localizes to the plasma
membrane and the endosomal compartments, and is part of the Arf family of GTPases
affecting vesicular trafficking and actin reorganization. As a GTPase, Arf6 cycles
through an inactive GDP-bound form, and an active GTP-bound form. Function-wise,
Arf6 has been implicated in many processes depending upon where recruitment and
activation occurs. At the plasma membrane, Arf6 has roles in the regulation of both
clathrin-dependent and clathrin-independent forms of endocytosis, as well as in cell
remodeling (D’Souza-Schorey et al. 2006). Arf6 may also be necessary in recycling
endosomes for movement back to the plasma membrane (D’Souza-Schorey et al. 1998).
The major downstream effectors of Arf6 that function in the regulation of actin
reorganization are Rac, PIP5K, and phospholipase D (PLD) (Donaldson 2003).
One of the earliest studies connecting Arf6 and macropinocytosis was conducted by
Honda et al. (1999). In this study, using activity assays against PIP5K, which generates
PIP2, they were able to observe PIP5K activation by Arf6, as well as a number of other
Arfs. Furthermore, they found that activation of PIP5K required phosphatidic acid (PA),
which is generated by PLD. In order to verify which Arf was physiologically responsible
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for PIP5K activation, they transfected C-terminal haemagglutinin (HA) epitope-tagged
Arfs and N-terminal myc epitope-tagged PIP5K in HeLa cells. What they found was that
both Arf6 and PIP5K localized on the plasma membrane, more specifically in ruffles
being formed at the membrane. They also found that PLD2 translocates to the plasma
membrane, corroborating their earlier result that PIP5K activation required PLD activity.
Furthermore, membrane ruffling was inhibited through the use of an Arf6 dominant
negative mutant. As further validation for the requirement of Arf6-activation of PLD for
macropinocytosis, a study carried out by O’Luanaigh et al (2002) found that PLD2 and
Arf6 activity together were required for membrane ruffling in mast cells. Another study
conducted the same year by Radhakrishna et al (1999) indicated that Arf6 activity
regulated the activity of Rac1, another protein important for actin reorganization and
macropinocytosis. In this study, they found that Arf6 and Rac1 colocalized to both the
plasma membrane and recycling endosomes in HeLa cells and primary human
fibroblasts, further verified through colocalization of transfected cells. Furthermore, their
role in macropinocytosis was suggested through the observation that cells expressing
wild-type Rac1 and Arf6 began to form ruffles after application of the G-protein-coupled
receptor agonist, bombesin, and ruffle formation was inhibited through by an Arf6
dominant negative mutant. Since then many more lines of evidence have appeared to
validate the role of Arf6 regulation in actin remodeling through PLD, PIP5K, and Rac1
(Brown et al. 2001; Hernandéz-Deviez et al. 2004; Boshans et al. 2000). Therefore, it is
apparent that Arf6 plays an important role in the regulation of macropinocytosis,
especially at the initial stages of forming membrane ruffles.

1.5.2 The Rho GTPases
In the regulation of actin dynamics and generation of membrane ruffles. Arf6 has been
suggested to be an upstream effector of the Rho family of GTPases, Rac1, Cdc42, and
RhoA (Osami et al. 2010, Donaldson 2003, Boshans et al. 2000). The direct connection
between Arf6 and these GTPases is unknown, however at least one study suggests that
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Arf6 may recruit Kalirin5, a Rho GTPase family GEF, to activate these proteins
downstream (Koo et al. 2007).

1.5.2.1 Rac1
The small GTPase, Rac1, is part of the subfamily of Rac proteins, also including Rac2,
Rac3, and RhoG (Ridley 2006). All 4 members of the Rac family of proteins localize the
plasma membrane, however Rac2 also localizes to the cytosol, while Rac3 and RhoG
localize to endosomes. Of the Rac family members, Rac1 has been the best studied. Rac1
is important for the function of many processes, such as lamellipodia formation,
membrane ruffling, the neuronal cell death response, neuronal morphogenesis, cell
motility, and phagocytosis (Stankiewicz et al. 2014). Generally speaking, the function of
Rac1 is in the regulation of actin polymerization and cytoskeletal changes. While the role
of Rac1 is implicated in the above processes, the exact pathways through which Rac1
regulates them is not clear, but what is commonly known is that Rac1 has been shown to
activate the WAVE complex and Pak1 (Eden et al. 2002; Steffen et al. 2004; Manser et
al. 1994; Zhang et al. 1998).
The WAVE complex is a well-described regulator of actin polymerization through its
association with the Arp 2/3 complex when activated, and is thought to be responsible for
much of the actin reorganization related activity that occurs from Rac1. The action of
WAVE on Arp2/3 is similar to WASp activity on Arp2/3, directly binding to and
activating Arp2/3, which goes on to initiate nucleation of actin monomers onto filaments
(Kurisu et al. 2009). As for Pak1 function, PAK1 has been shown in a number of studies
to regulate actin cytoskeleton remodeling, and more importantly requiring Rac activation
to do so (Sells et al. 1997; Daniels et al. 1998; Dharmawardhane et al. 2000). This is
corroborated by another study demonstrating Pak1 stimulation of macropinocytosis
through observation of dextran uptake in the presence of Pak1 mutants. Additionally,
they also demonstrated that a Rac1 dominant negative mutant was unable to inhibit this
stimulation of macropinocytosis when co-expressed, suggesting that Pak1 stimulation
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ROCK1/2
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Figure 3. Regulation of macropinosome formation. A number of proteins have been
implicated in the formation of macropinosomes including the Rho GTPases, PLD, and
PIP5K. The diagram above depicts what role they and their downstream effectors have
been shown to play in the initiation of macropinocytosis, especially in actin nucleation, as
depicted by arrows. The pathway towards actin nucleation begins with Arf6-activation as
we believe Arf6 is the major regulator in the macropinocytosis of APP.
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downstream of Rac1 may be sufficient for macropinocytosis to occur (Dharmawardhane
et al. 2000). Pak1 has also been suggested to regulate Arp2/3 activity through the p41Arc subunit of the Arp2/3 complex (Vadlamudi et al. 2004) although the exact
mechanism is unknown.
The association between Rac1 and Alzheimer’s disease has been noted in multiple
studies, however many of these studies report conflicting effects and levels of expression
in Alzheimer’s disease. A study performed in COS-7 cells showed that Rac1 inhibition
was able to decrease γ-secretase activity on APP. Production of the AICD was decreased
after Rac1 inhibition, while accumulation of APP CTFs occurred. However, the way this
process occurs is a bit unintuitive. What Boo et al (2008) found was that using the
inhibitor for Rac1, NSC23766, increased PS1 interaction with Notch, another substrate of
γ-secretase. This increased interaction resulted in increased cleavage of Notch by the γsecretase and decreased cleavage of APP CTFs. Interestingly, another study in primary
hippocampal neurons and HEK293 cells showed decreased levels of APP mRNA and
protein as a result of Rac1 inhibition using the same inhibitor. This decreased APP
mRNA and protein levels were also shown to translate into decreased production of Aβ40
and Aβ42. Lastly, this study revealed a site within the APP promoter for Rac1 regulation
(Wang et al. 2009). Rac1 inhibition leading to decreased Aβ production has also been
demonstrated using another Rac1 inhibitor, EHT 1864. Using EHT 1864, Rac1 inhibition
was shown decrease γ-cleavage, resulting in increased concentrations of the C99
fragment. Perhaps most relevant to the current study, this inhibition did not reflect a
direct effect on γ-secretase activity, as inhibition of Rac1 did not decrease Notch cleavage
(Désiré et al. 2005). This suggests a possible role for Rac1 inhibition in the trafficking of
APP to the intracellular compartment containing γ-secretase activity.

1.5.2.2 Cdc42
The second important Rho GTPase for actin dynamics is Cdc42. Cdc42 localizes to the
plasma membrane and the Golgi (Ridley et al. 2006). Aside from its role in the regulation
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of clathrin-independent endocytosis, Cdc42 is well-known for its role in filopodia and
microspike formation, and neuron growth and development (Kozma et al. 1995; Ridley et
al. 1992; Aoki et al. 2004; Li et al. 2002). However, no matter which process, Cdc42
regulates these actions through stimulation of actin assembly and reorganization. In this
aspect, the main activity of Cdc42 is its binding and activation of Wiskott - Aldrich
syndrome protein (WASp), which as noted above is able to bind to the Arp2/3 complex to
initiate actin nucleation. The association between Cdc42 and WASp has been well
documented over the years, and the mechanism of its action has been well described
(Aspenström et al. 1996; Kolluri et al. 1996).
WASp was initially discovered through the identification of its gene in Wiskott-Aldrich
syndrome, hence the name (Derry et al. 1994). There are two forms of WASp currently
known, WASp, and N-WASp, which is highly expressed in neural tissue (Takenawa et
al. 2007). The role of WASp is to facilitate actin remodeling through the activation of the
Arp 2/3 complex, similar to WAVE (Machesky et al. 1998). WASp is usually found in a
constitutively inactive, folded conformation that covers a site required for Arp2/3
binding. Once bound to PIP2 and Cdc42 the protein becomes activated and unfolds to
reveal this domain. Furthermore, binding of either PIP2 or Cdc42 promotes the binding
of the other, promoting activation in a co-operative manner (Rohatgi et al. 2000). After
this occurs, Arp2/3 is stimulated to initiate actin nucleation.
Apart from events regarding actin nucleation, and its necessity for actin reorganization,
evidence for a possible role of Cdc42 in the formation of macropinosomes is almost nonexistent in the literature. Only one example exists highlighting the possible role of Cdc42
in the regulation of macropinocytosis. In dendritic cells, the ability to produce
macropinocytosis is lost as they mature. Garret et al connected this loss in
macropinocytic ability to a decrease in the Cdc42-GTPase. In order to test this hypothesis
further, they demonstrated that a Cdc42 dominant negative inhibitor for Cdc42 caused
ablation of the macropinocytic response in immature dendritic cells. Furthermore, upon
delivery of a constitutively active Cdc42 or a Cdc42 GEF revived the capacity for
macropinocytosis in mature dendritic cells which lost it (Garrett et al. 2000). As for
Cdc42 in relation to Alzheimer’s disease, there have been few connections demonstrated;
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however, one of these is a connection between WASp and Alzheimer’s disease. The few
studies linking Cdc42 and Alzheimer’s disease show that fibrillar Aβ increases Cdc42
activity, and also that Cdc42 is upregulated in Alzheimer’s disease populations (Zhu et
al. 2000; Moon et al. 2013; Mendoza-Naranjo et al. 2007). Furthermore, the study from
Mendoza-Naranjo et al (2007) suggested that this increase in Cdc42 occurred at the
plasma membrane, and resulted in increased actin polymerization activity. As for WASp
in Alzheimer’s disease, N-WASP protein expression has been found to be increased in
Alzheimer’s disease brains (Kitamura et al. 2003).

1.5.2.3 RhoA
The last Rho GTPase that will be discussed is RhoA. RhoA is part of the Rho subfamily
of proteins of which there are three major isoforms: RhoA, RhoB, and RhoC. All three
Rho isoforms localize to the plasma membrane, however RhoA and RhoC also localize to
the cytosol, while RhoB also localizes the endosome (Ridley 2006). The first and most
relevant function of RhoA is in the regulation of actin dynamics. However, RhoA can
also upregulate apoptosis, acting antagonistically to Rac1 which suppresses apoptosis.
Through this tug-of-war process, Rac1 and RhoA are believed to regulate neuronal cell
death and neuron growth (Stankiewicz et al. 2014). As evidence for this, Sanno et al
found that mice expressing a mutant that causes inhibition of RhoA showed a greater
number and density of neurons in the somatosensory cortex, and the overexpression of
RhoA in cortical neurons caused an increased rate of apoptosis (Sanno et al. 2010). RhoA
activates three noteworthy proteins in the regulation of actin reorganization, Rhoassociated coiled-coil containing protein kinase (ROCK)-1, ROCKII, and mDia1. mDia1
has been shown to be able to facilitate nucleation of actin (Li et al. 2003). In contrast,
ROCKI and ROCKII are understood to be inhibitory in actin reorganization, although
there are conflicting reports for this. For example, they appear to stimulate apoptosis and
inhibit axon growth; however, they have also been shown to stimulate cell proliferation
and the formation of stress fibers downstream of RhoA (Julian et al. 2014; Fujita et al.
2014).
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There are very few studies linking RhoA and macropinocytosis, as well as RhoA and
Arf6, which will be discussed below. In a study conducted by Zawistowski et al (2013)
the authors observed the attenuation of RhoA activation in the initial stages of
macropinosomes formation. This was then followed by increased RhoA activity after
closure of the vesicle. In another study conducted by Kurokawa and Matsuda (2004),
RhoA activity was observed to be increased in membrane ruffles and required Cdc42
activity to occur. Suppression of this activity with a dominant negative mutant was also
able to override Rac1-stimulated membrane ruffling. The regulation of RhoA by Arf6 has
been documented previously in the regulation of actin dynamics, but never further
connected to macropinocytosis (Boshans et al. 2000; Kim et al. 2015).
There is growing evidence that RhoA may be important in Alzheimer’s disease. This is
best seen with inhibitors against ROCKs, which are downstream of RhoA, and reduce Aβ
production (Zhou et al. 2003; Herskowitz et al. 2013). In another study, RhoA was found
at elevated levels surrounding amyloid plaques in mice expressing the APP Swedish
mutation (Petratos et al. 2008). In agreement with a connection between RhoA and
Alzheimer’s disease, Huesa et al (2010) indicated that RhoA localizes to synapses and
dendritic microtubules in neurons, which changed in APP Swedish mutation mice to
become more localized in the neurite and less so in the synapse. Furthermore, in AD
patient brains, RhoA was found to localize to neurons, colocalizing with
hyperphosphorylated Tau protein.

1.5.3 Phospholipase D
The PLDs are a small family of proteins consisting of PLD1, PLD2, PLD3, PLD4, and
PLD5 in humans. Of these proteins, PLD1 and PLD2 are the major isoforms, although
PLD3 has been found to have implications in Alzheimer’s disease (Cruchuga et al. 2014;
Satoh et al. 2014). PLD1 is localized primarily to the membranes of organelles in the cell,
such as endosomes, lysosomes, and the Golgi. PLD2 on the other hand localizes to the
plasma membrane. PLD3, which localizes to the endoplasmic reticulum (ER), has also
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been seen to be highly expressed in neurons, with Alzheimer’s disease brains showing
greatly reduced expression (Cruchuga et al. 2014; Frohman 2015).
The most commonly studied function of PLD is its capacity to hydrolyze
phosphatidylcholine (PC), the most abundant membrane phospholipid, into choline and
PA. PA itself is able to produce negative curvature in membranes when accumulated due
to a small, negatively charged group on its head; this function may facilitate the
generation of vesicles at the membrane. PA also acts as a lipid anchor for a number of
guanine nucleotide exchange factors (GEFs) that then activate other proteins such as
Rac1 and Ras. As noted above, PA can also activate recruited proteins such as PIP5K
(Frohman 2015).
To date, there appear to only be two studies connecting PLD function to
macropinocytosis. The first study, conducted by Haga et al (2009), found that PLD1 was
required for EGF-stimulated macropinocytosis in Cos7 cells. Furthermore, PLD1facilitated macropinocytosis required the activation of CtBP1/BARS to occur. The other
study, from Mettlen et al (2006) found that ruffling and macropinosome formation was
annulled through the use of PLD inhibitors. However, while PA does not directly regulate
macropinocytosis, PA does regulate other proteins that have been implicated in actin
reorganization, such as PIP5k as mentioned above (Roach et al. 2012). PLD and by
extension PA, have also been found to be necessary for phagocytosis with PLD1 and
PLD2 possibly playing complementary roles, as PLD1 appears in internalized and
forming phagosomes, while PLD2 only localizes to forming phagosomes (Corrotte et al.
2006; Iyer et al. 2004).

1.5.4 PIP5-Kinase
Phosphatidylinositol 4-phosphate 5-kinase (PIP5K) is a phospholipid kinase, as its name
suggests,

whose

main

role

is

the

phosphorylation

of

PI(4)P

to

produce

phosphatidylinositol 4,5-di-phosphate (PI(4,5)P2) or simply PIP2. PIP5K activity is
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regulated by various upstream hormones, neurotransmitters, and growth factors, in order
to temporally and spatially control PIP2 generation within the cell. In mammals there are
three distinct isoforms of PIP5K that follow α, β, γ nomenclature. Furthermore, within the
PIP5Kγ isoform, there exist multiple splice variants. In terms of localization, PIP5Kα
localizes to the nucleus and cytosol, PIP5Kβ localizes to the perinuclear region in small
punctate structures, and PIP5Kγ localizes to focal adhesions, the cytosol, or the nucleus
depending on the splicing variant. However, when stimulated, both PIP5Kα and PIP5Kβ
quickly localize to the plasma membrane and begin to generate PIP2 (Funakoshi et al.
2011).
PIP5K is regulated upstream by a large number of proteins, most of which are activators
of PIP5K and important to actin dynamics. The few that are most relevant to this study
are Arf6, the Rho GTPases, and PA. AP-2, a regulator of clathrin-mediated endocytosis
as mentioned above, also activates PIP5K. Beginning with Arf6, PIP5K activation
through Arf6 was first identified by Martin et al (1996) in the plasma membranes of
HL60 cells where they discovered that the Arf protein could cause overproduction of
PIP2 through PIP5K activity. A few years after this, the study by Honda et al (1999)
discussed previously as well as a study carried out by Jones et al (2000) substantiated
these results for Arf activation of PIP5K. However, the Honda study showed PIP5K
activation by Arf6, while the Jones study demonstrated PIP5K activation by Arf1. One
interesting difference in the activation pathways for the two Arf6 proteins on PIP5K was
the role of PA. In the Honda study it was noted that PA was required for Arf6-mediated
PIP5K activity, indicating a role for PLD in this pathway as well. In contrast, the Jones
study showed that PA activity was actually inhibitory, rather than stimulatory. At present,
Arf6-activated PIP5K has been shown to regulate a variety of trafficking systems,
including membrane ruffling, clathrin-mediated endocytosis, endosomal trafficking, and
even some forms of exocytosis. Unfortunately, the function above most relevant to the
current study, membrane ruffling, occurs through currently unidentified means.
Other than Arf6, the Rho GTPases Rac1, Cdc42, and RhoA have also been shown to
activate PIP5Ks, providing additional links for PIP5K activity in the regulation of actin
remodeling (Tolias et al. 2000; Chong et al. 1994; Weernink et al. 2004). However, this
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activation, at least for RhoA and Rac1, seems to be indirect as the study by Honda et al
(1999) looking at a PIP5K activity assay observed that RhoA and Rac1 association with
PIP5K was not able to directly activate PIP5K. These findings have been supported, at
least for RhoA, by a number of studies that implicate Rho-associated coiled coil-forming
protein kinase (ROCK), a downstream effector of RhoA, in the direct activation of PIP5K
(Yamazaki et al. 2002; Oude Weernink et al. 2000). Lastly, activation of PIP5K by PA
has been demonstrated in a number of other studies apart from the finding in Honda et al.
All three of the PIP5K isozymes have been found to be activated by PA (Isihara et al.
1998; Jenkins et al. 1994; Moritz et al. 1992). Unfortunately, whether this activation is
directly from PA or through indirect means, as displayed in the Arf6 activation of PIP5K,
is currently unknown. As evidence for the role of PIP2, which as discussed above is
generated by PIP5K, in macropinocytosis, PIP2 has been to shown increase in
concentration at the formation of macropinosomes (Araki et al. 2007). Aside from this,
PIP2 is well known to play a role in actin rearrangements (Yin et al. 2003).

1.6 Rationale and Aims
Our laboratory has discovered evidence for the colocalization of APP, presenilin-1, and
LAMP1 in lysosomes, as well as γ-secretase activity in lysosomes, implicating the
lysosome as a possible site of APP processing into the toxic Aβ (Pasternak et al. 2003).
We have also uncovered a novel pathway for APP processing in which APP is rapidly
internalized from the plasma membrane directly to lysosomes, in a pathway completely
separate from endocytosis arising from early and late endosomes (Lorenzen et al. 2010).
Through confocal microscopy of fixed and live cells, and electron microscopy, we were
able to see the internalization of APP at the cell surface into large >500 nm vesicles,
which then quickly fused with lysosomes (Tang et al. 2015). Furthermore, when
transfected with Arf6 bearing a dominant negative mutation, this pathway was blocked,
while leaving endocytosis of APP into early endosomes intact. By using the Arf6
dominant negative mutant we were also able to show that the observed decrease in
lysosomal trafficking of APP was accompanied by a significant reduction in Aβ
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production. Lastly, through immunostaining of human brains, we were able to show an
increase in Arf6 expression throughout the hippocampus with the pathogenesis of
Alzheimer’s disease (Tang et al. 2015). With such promising evidence for the role of
Arf6 in Alzheimer’s disease we set out to explore the pathway through which Arf6 may
mediate the macropinocytosis of APP into lysosomes.
Our previous results demonstrate a pivotal role for Arf6 in APP trafficking in lysosomes
and in Aβ production. Furthermore, this mechanism is separate from clathrin-mediated
endocytosis and appears to form large (>500 nm) vesicles, consistent with
macropinocytosis. Consequently, we speculate that members of the Rho GTPases, Rac1,
Cdc42, and RhoA, may play a role downstream of Arf6 in this trafficking, due to multiple
lines of evidence linking these proteins to macropinocytosis, actin dynamics regulation,
and the ability to be regulated by Arf6. Therefore, I hypothesize that macropinocytosis
of APP to the lysosomes and Aβ production is regulated by the actin remodeling
regulators Rac1, Cdc42, and RhoA downstream of Arf6. The two principal objectives
of this project are: 1) To determine if Rac1, Cdc42, and RhoA can regulate
macropinocytosis of APP to the lysosomes. 2) If the Rho GTPases can regulate
macropinocytosis, can they can regulate Aβ production? In this thesis, using inhibitors or
siRNA knockdown against Rac1, Cdc42, or RhoA and confocal microscopy, I will
demonstrate that macropinocytosis of APP directly to lysosomes can be blocked.
Furthermore, using the same inhibitors I will demonstrate that both Aβ40 and Aβ42
production can be reduced.
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Chapter 2: Materials and Methods

2.1 Antibodies and Reagents
Antibodies purchased were: Mouse Anti-HA from Sigma-Aldrich, Rabbit Polyclonal
Anti-Cdc42 from Santa Cruz Biotechnology, Rabbit Polyclonal Anti-Rac1 from Santa
Cruz Biotechnology, and Rabbit Polyclonal Anti-RhoA from Santa Cruz Biotechnology.
SN56 cells were obtained from Dr. Jane Rylett. Neuro-2a (N2A) cells were purchased
from ATCC. Fluorescently-labeled secondary antibodies and Zenon Alexa Fluor 647
Mouse IgG1 Labeling Kit were purchased from Life Technologies (California). EHT
1864, ML 141, SR 3677 inhibitors and dimethyl sulfoxide (DMSO) were purchased from
Sigma-Aldrich. Aβ40 and Aβ42 ELISA assay kits were purchased from Life
Technologies (California). Mini-PROTEAN TGX Precast Gels were purchased from BioRad. Dulbecco’s modified Eagle’s medium (DMEM), minimum essential media (MEM),
fetal bovine serum (FBS), heat inactivated fetal bovine serum, Hank’s balanced salt
solution (HBSS), penicillin, streptomycin, and trypsin-EDTA were all purchased from
Gibco.

2.2 DNA Constructs
The βAPP construct used was generated by Dr. Pieter Anborgh, and was previously
demonstrated to traffic and behave in the same way as wild-type APP (Lorenzen et al.
2010). A cDNA encoding APP 750-YFP, a gift from Dr. Bradley Hyman, was used to
generate this cDNA. First, the signal sequence encoding the N-terminal 17 amino acid
signal sequence of APP and the L-E residues required for signal peptide cleavage
(Lichtenthaler

et

al.

1999)

5’GCTAGCATGCTGCCCGGTTTG3’

was

cloned

using

the

primers
and
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5’ACGCGTAGCGTAATCTGGAACATCGTATGGGTACTCCAGCGCCCGA3’,
adding a 3’ haemagglutinin (HA) tag, a 5’Nhe1 site, and a 3’Mlu1 site. In order to then
generate the shortened βAPP construct, the C-terminal 112 amino acids that begin 12
amino acids upstream of the β-cleavage site was cloned using the primers
3’ACGCGTTTCCTGAACTGCTGCCCCGGCTGCTGCATGGAGCCC5’

and

3’ATCAAGACGGAGGAGATCTCTG5’. In addition to the shortened construct, these
primers also add a 3’MLu1 site and a 5’Sal1 site. The first and second products were then
ligated into pEYFP-N1 or pECFP-N1 vectors (Clontech). The βAPP construct was
generated to reduce the possibility of APP being cleaved by a non-secretase enzyme.
Constructs similar to βAPP have demonstrated the ability to undergo both β- and γcleavage (Grimm et al. 2008). Furthermore, βAPP has been previously demonstrated to
have the same intracellular distribution as well as lysosomal trafficking as that of full
length APP (Lorenzen et al. 2010).
Expression constructs for regulatory proteins bearing dominant negative mutations were
YFP-RhoA-T19N, GFP-Rac1-T17N, and eGFP-Cdc42-T17N, all generous gifts from Dr.
Susan Meakin. These dominant negative mutants function by abolishing the protein’s
affinity for GTP, causing them to tightly bind GEFs and further preventing them from
activating the normal endogenous GTPases (Wong et al. 2006). Dominant negative
constructs for these proteins bearing fluorescent fusion proteins have been shown
previously to be functional (Kurokawa et al. 2005). Regulatory proteins bearing
constitutively activating mutations were YFP-RhoA-Q63L, GFP-Rac1-Q61L, and YFPCdc42-G12V, all generous gifts from Dr. Susan Meakin.

The constitutively active

mutations of these proteins causes decreased intrinsic GTPase activity of the mutant
proteins, mimicking a constantly GTP-bound state (Hope et al. 2008, Longenecker et al.
2003, Johnson 1999). Constitutively active constructs for these proteins bearing
fluorescent fusion proteins have also been shown previously to be functional (Kurokawa
et al. 2005, Yoshizaki et al. 2003, Itoh et al. 2002). LAMP1-YFP was a generous gift
from Dr. Walter Mothes and recloned into mCherryFP. Rab5-mRFP was a generous gift
from Dr. Stephen Ferguson.
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2.3 Cell Culture and Transfection
SN56 neuroblastoma cells were grown in DMEM, supplemented with 10 % (v/v) heat
inactivated FBS (Gibco), and 100 μg/ml penicillin/streptomycin (Gibco). Cells were kept
in 25 cm2 or 75 cm2 flasks (Falcon) in an incubator at 37 °C in a humidified atmosphere
containing 5 % CO2 and were split every 3-4 days. Cells were seeded at a density of 3 x
105 cells/35-mm dish (MatTek) one day prior to transfection date. Cells were then
transiently transfected with Lipofectamine 2000 according to manufacturer’s instructions
(Invitrogen) in serum free medium. Following an incubation period of 24 h, cells were
differentiated with the addition of 1mM dibutyryl cyclic AMP (dbcAMP; Sigma) to
serum free medium (Hammond et al. 1986).
Neuro-2a neuroblastoma cells were grown in MEM, respectively supplemented with 10
% (v/v) FBS (Gibco), and 100 μg/ml penicillin/streptomycin (Gibco). Cells were kept in
25 cm2 or 75 cm2 flasks (Falcon) in an incubator at 37 °C in a humidified atmosphere
containing 5 % CO2 and were split every 3-4 days. Cells were seeded at a density of 4 x
105 cells/35-mm dish (MatTek) one day prior to transfection date. Cells were then
transiently transfected with TurboFect according to manufacturer’s instructions (Life
Technologies) in serum free medium. Following an incubation period of 24 h, cells were
differentiated with serum withdrawal in MEM.

2.4 Inhibitor Treatments
Following differentiation, cells received fresh serum-free medium at indicated
concentrations of EHT 1864, ML 141, or SR 3677 dissolved in DMSO. 0.1 % DMSO
(v/v) serum-free medium was used as a vehicle control. Cells incubated with ML 141
were incubated for 1 hour at 37 °C and 5 % CO2 before being subjected to internalization
experiments. Cells incubated with SR 3677 were incubated for 6 hours at 37 °C and 5 %
CO2 before being subjected to internalization experiments. Cells incubated with EHT
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1864 were incubated for 18 hours at 37 °C and 5 % CO2 before being subjected to
internalization experiments.

2.5 Confocal Microscopy
Imaging was performed on a Zeiss LSM-510 META laser scanning microscope using a
Zeiss 63X 1.4 numerical aperture oil immersion lens. The optical section thickness was
typically 1 micron. ECFP fluorescence was imaged using 458 nm excitation laser and a
458-480 filter set. EGFP and YFP fluorescence was visualized using a 488 nm excitation
laser and a BP 500-550 filter set. mRFP and mCherryFP fluorescence was visualized
using a 543 nm excitation laser and a LP 560 filter. AlexaFluor 647 fluorescence was
imaged using a 633 nm excitation laser, and a LP 650 filter.

2.6 Antibody Cell Surface Labeling
Anti-HA antibody (Sigma-Aldrich) was labeled with Alexa Fluor 647 using a Zenon
Alexa Fluor 647 Mouse IgG1 Labeling Kit (Life Technologies) according to
manufacturer’s instructions. All internalization experiments were subject to fixed timecourse studies. A freshly prepared conjugate was incubated with cells in DMEM, for
SN56 cells, or MEM, for N2A cells, on ice for 30 minutes. The conjugate was removed
and the cells were washed twice in HBSS pre-warmed to 37 °C. After washing, warm
HBSS was added to the dishes and the cells were incubated at 37 °C and 5 % CO2 for
indicated times. Following incubation, cells were fixed with 4% paraformaldehyde on ice
for 15 minutes. Cells chosen for study had to show strong expression of both βAPP and
compartment marker constructs, through strong fluorescence, in addition to normal
morphology. Experiments were replicated 3 or 4 times as indicated for each
treatment/construct, with 15 cells sampled at each time point.
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2.7 Aβ40 and Aβ42 ELISA
N2A cells were plated at a density of 5 x 105 cells into each well of a 6-well plate with 2
mL of MEM, with the addition of 10% FBS (v/v), overnight. The following day cells
were transfected with HA-βAPP-CFP for 24 hr. For Aβ40 ELISAs following
transfection, the cells were given 1 mL of fresh serum-free medium in each well and 10
μM of the indicated inhibitor or 0.1 % DMSO diluted into the medium and then
incubated for 24 hours. For Aβ42 ELISAs following transfection, the cells were given 1
mL of fresh serum-free medium in each well and 10 μM of the indicated inhibitor or 0.1
% DMSO diluted into the medium and then incubated for 48 hours. After culture, 500 μL
of medium was collected and assayed using an ultrasensitive Aβ40 or Aβ42 ELISA kit
(Life Technologies) according to the manufacturer’s instructions. Experiments were
replicated 4 times for Aβ40 and 3 times for Aβ42 and data normalized against the
control. Data was plotted and analyzed using GraphPad Prism 6.0 software and an
unpaired t-test with a 95% confidence interval.

2.8 siRNA Knockdown
SN56 or N2A cells were split as described in the cell culturing subsection. Stealth
siRNAs

(Invitrogen)

were

purchased

(GCCUGCUCAUCAGUUACACGACCAA),
(CCUUUCUUGCUUGUUGGGACCCAAA).

for

and
Silencer

Select

Rac1
Cdc42

siRNA

(Life

Technologies) was purchased for RhoA (AGCCUUGAUAGUUUAGAAAtt). Cells were
transfected with increasing amounts of siRNA as indicated by Lipofectamine 2000 (Life
Technologies) manufacturer’s instructions and western blotted to demonstrate
knockdown. Cell lysates were collected 3 days after transfection and assayed by western
blotting with a 1:1000 concentration of Anti-Rac1 (Santa Cruz Biotechnology), AntiRhoA (Santa Cruz Biotechnology), or Anti-Cdc42 (Santa Cruz Biotechnology)
antibodies.
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For trafficking studies, cells were transfected with HA-βAPP-CFP, LAMP1-mCherryFP,
and 10 nM of siRNA Negative Control, as well as 400 nM of Rac1 siRNA, 200 nM
Cdc42 siRNA, or 50 nM RhoA siRNA depending on the experiment. Following 48 hours
of transfection cells were differentiated for 1 day and then surface labeled with
AlexaFluor 488 Zenon-labeled anti-HA antibodies as previously described and allowed to
internalize for 15 minutes at 37 °C. Cells were then fixed with 4 % paraformaldehyde.
Following fixation cells were imaged using confocal microscopy and colocalization
percentage between βAPP and LAMP1 channels was measured. Experiments were
replicated 3 times and data normalized against the control. Data was plotted and analyzed
using GraphPad Prism 6.0 software.

2.9 Protein Extraction and Western Blotting
SN56 or N2A cells were plated on 60 mm dishes (Falcon) at a cell density of 1.5 x 106
per 60 mm plate. The following day, plates were then transfected with the appropriate
DNA constructs and siRNA transcripts. Following 2 days of incubation and 1 day of
differentiation, cells were washed in cold PBS and lysed with NP40 lysis buffer (20 mM
Tris pH 8.0, 137 mM NaCl, 10 % glycerol, 1 % IGEPAL/NP40) for 30 min at 4 °C. Cells
were then scraped, sonicated, and centrifuged at 14,000 rpm for 10 minutes at 4 °C to
remove insoluble material. Protein quantification of supernatant was performed using a
Pierce BCA protein assay kit (Life Technologies) according to manufacturer’s
instructions. Total cell lysates were separated in a 12% SDS-PAGE gel by
electrophoresis at 140V for approximately 1 hour. Protein was then transferred onto
polyvinylidene fluoride (PVDF) membranes using semi-dry transfer at 25V for 30
minutes. Immediately after transfer, membranes were stained with Ponceau solution to
visualize quality and location of transferred bands.
PVDF membranes were first probed with Rac1 (1:1,000), Cdc42 (1:1000), RhoA (1:
1,000), or α-tubulin (1: 10,000) (Sigma) antibodies, then incubated in HRP-mouse
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antibodies (1: 10,000) (Sigma), developed using ECL and imaged. Quantification of
western blot images was done using Image Lab software.

2.10 Data Quantification and Analysis
Colocalization analysis was performed on confocal optical sections using Imaris 7.0.2
with Imaris Colocalization module (Bitplane). Using Imaris, thresholds were set to select
only the brightest 2% of pixels in the HA-tagged βAPP channel, and the brightest pixels
past a set pixel intensity that demarcated compartment markers, to ensure only lysosomes
or endosomes were considered in analysis. Imaris then generated a colocalization
percentage by determining the number of pixels (above threshold) of surface labeled APP
that are colocalized with the lysosomal or endosomal marker. 10-15 cells were measured
from multiple plates for each replication of an experiment. Graphing and statistical
analysis was performed using GraphPad Prism 6.0 using one-way ANOVA with Tukey
post-test with a 95% confidence interval.
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Chapter 3: Results

3.1 Rapid transit of cell surface-labeled APP to the lysosome
in N2A cells
In these experiments we adopted the N2A cell line because it has been shown to exhibit
neuronal morphology (Tremblay et al. 2010). This cell line was derived from a mouse
neuroblast that expresses neuronal morphology and used in many lines of neuronal study.
Many of the pilot experiments in our lab were previously performed in SN56 cells, a
cholinergic hybrid cell line made by fusing septal cholinergic neurons with
neuroblastoma cells. The N2A cell line was adopted here because of concerns that the
SN56 cell line was senescing due to high passage number. However, some experiments
with negative results here were replicated in SN56 cells to determine if there were traits
missing in the N2A cells.
We first set out to confirm that our basic internalization/macropinocytosis experiment
works in N2A cells. A basic 15-minute internalization of APP was replicated from a
previous study (Lorenzen et al. 2010).

Cells were transfected with HA-βAPP-CFP

(green) and LAMP1-mCherryFP (red) then later surface labeled with anti-HA conjugated
AlexaFluor 647 Zenon antibodies on ice for 30 minutes. Cells were then allowed to
internalize at 37 °C for 15 minutes, or kept on ice as a 0-minute internalization time point
(Fig. 3). Cells were then fixed and imaged using confocal microscopy and analyzed for
colocalization. To do this, we used Imaris software to set thresholds to identify the 2%
brightest pixels from each channel and to calculate the percentage of green (APP) pixels
that were colocalized with red (LAMP1) pixels. Representative images are shown in
Figure 4A. Results confirm that internalization of APP occurs in N2A cells after 15
minutes. N2A cells exhibit a large increase in colocalization of βAPP and LAMP1 after a
15-minute internalization (25.5 % ± 0.9) compared to 0 minutes of internalization (3.5 %
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Figure 4. Transport of APP to lysosomes occurs in N2A cells. A) N2A cells
transfected with HA-βAPP-CFP and Lamp1-chFP (red), surface-labelled with Zenon-647
anti-HA antibodies (green) for 30 minutes, and then fixed or incubated for 15 minutes at
37ºC. After 15 minutes of incubation at 37ºC, colocalization between HA-βAPP and
Lamp1 was observed. B) Quantification of colocalization analysis between HA-βAPP
and Lamp1 channels for 0 minutes and 15 minutes from 1 experiment. Significance
denoted by * (P < 0.05) Scale bar = 5 μm.
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Figure 5. RhoA dominant negative or constitutively active mutants do not affect
internalization of APP to lysosomes in SN56 cells. A) SN56 cells transfected with HAβAPP-CFP, Lamp1-chFP (red), and a RhoA dominant negative-YFP or a RhoA
constitutively active-YFP mutant, surface-labelled with Zenon-647 anti-HA antibodies
(green) for 30 minutes, and then fixed or incubated for 15 minutes at 37ºC. After 15
minutes of incubation at 37ºC, colocalization between HA-βAPP and Lamp1 was
observed. B) Quantification of colocalization analysis between HA-βAPP and Lamp1
channels with standard error for control, RhoA-DN, and RhoA-CA from 5 replicates, no
significance between any groups (p<0.05). Scale bar = 5 μm.
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± 1.3). Three replicate experiments, with each experiment examining 10 cells, were
analyzed for this experiment.

3.2 Transfection of SN56 cells with RhoA mutants does not
affect internalization of APP to lysosomes
RhoA was hypothesized to be downstream of Arf6, because of its effects on actin
polymerization. In order to determine if RhoA was able to affect internalization, SN56
cells were co-transfected with HA-βAPP-CFP, LAMP1-mCherryFP a compartment
marker for lysosomes, and either RhoA-T19N-YFP, a dominant negative mutant, or
RhoA-Q63L-YFP, a constitutively active mutant. After differentiation, cells were
surface-labeled with anti-HA conjugated AlexaFluor 647 antibodies, internalized for 15
minutes, fixed, and then imaged with confocal microscopy. Transfection of mutants into
cells was observed through fluorescence of the YFP- or GFP-tagged mutants. The colocalization of the brightest 2 % of pixels from the anti-HA and LAMP1 channels was
assessed to determine internalization of APP into lysosomes (Figure 5B). Representative
images are shown in Figure 5A. Data are shown as mean percent colocalization ± SEM,
and quantification used at least 10 representative cells for each replicate for 5 replicate
experiments. There were no significant differences in APP-LAMP1 colocalization
between control plates (22.4 % ± 2.6) and RhoA-DN cells (25.1 % ± 4.4) or RhoA-CA
cells (22.4 % ± 2.8). Using a one-way ANOVA with a post-hoc Tukey test, for analysis,
these differences are not statistically significant. These results would seem to indicate
that RhoA does not have an effect on APP trafficking to lysosomes in SN56 cells.

49

A
Anti-HA

LAMP1

Colocalization

Mutant

Rac1T17N
DN

Rac1Q61L

30

20

10

c
a
R

R

a

c

1

1

-C

-D

tr
n
o
C

A

N

l

0
o

B

H A - L a m p 1 C o lo c a liz a t io n ( % )

CA

Figure 6. Rac1 dominant negative or constitutively active mutants do not affect APP
internalization to lysosomes in SN56 cells. A) SN56 cells transfected with HA-βAPPCFP, Lamp1-chFP (red), and a Rac1 dominant negative-GFP or a Rac1 constitutively
active-GFP mutant, surface-labelled with Zenon-647 anti-HA antibodies (green) for 30
minutes, and then fixed or incubated for 15 minutes at 37ºC. After 15 minutes of
incubation at 37ºC, colocalization between HA-βAPP and Lamp1 was observed. B)
Quantification of colocalization analysis between HA-βAPP and Lamp1 channels with
standard error for 15 minute incubations at 37ºC for control, Rac1-DN, and Rac1-CA
from 4 replicates, no significance between any groups (p<0.05). Scale bar = 5 μm.
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3.3 Transfection of SN56 cells with Rac1 mutants does not
affect internalization of APP to lysosomes
The next possible mutants downstream of Arf6 to investigate were those for Rac1.
Similar to RhoA, Rac1 plays an important role in actin reorganization critical to the
formation of macropinosomes and is known to be downstream of Arf6 (Donaldson 2003).
To examine the role of Rac1 in the trafficking of APP to lysosomes SN56 cells were
used. Cells were co-transfected with HA-βAPP-CFP, LAMP1-mCherryFP, and either
Rac1-T17N-GFP, a dominant negative mutant, or Rac1-Q61L-GFP, a constitutively
active mutant. Cells were surface-labeled with anti-HA conjugated AlexaFluor 647
antibodies, internalized for 15 minutes, fixed, and then imaged with confocal microscopy.
Transfection of mutants into cells was observed through fluorescence of the GFP-tagged
mutants. The co-localization of the brightest 2 % of pixels from the anti-HA and LAMP1
channels was assessed to determine internalization of APP into lysosomes (Figure 6B).
Representative images are shown in Figure 6A. Data are shown as mean percent
colocalization ± SEM, and quantification used at least 10 representative cells for each
replicate for 4 replicate experiments. Cells in control plates (20.1 % ± 2.9) were not
significantly different from those in cells with Rac1-DN (25.3 % ± 2.3) or Rac1-CA (23.4
% ± 3.4) mutants. Using a one-way ANOVA with a post-hoc Tukey test, for analysis,
these differences are not statistically significant. These results indicate that transfection of
a Rac1 mutant does not affect APP trafficking to lysosomes in SN56 cells.

3.4 Transfection of N2A cells with Rac1 mutants does not
affect internalization of APP to lysosomes
Using a newer N2A cell line also exhibiting neuronal morphology we wanted to see if the
former negative result with both dominant negative and constitutively active mutants
were because of the high passage number of the SN56 cell line. N2A cells were again cotransfected with HA-βAPP-CFP, LAMP1-mCherryFP, and either Rac1-T17N-GFP, a
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dominant negative mutant, or Rac1-Q61L-GFP, a constitutively active mutant. Cells were
surface-labeled with anti-HA conjugated AlexaFluor 647 antibodies, internalized for 15
minutes, fixed, and imaged using confocal microscopy. Transfection of mutants into cells
was observed through fluorescence of the GFP-tagged mutants. The co-localization of the
brightest 2 % of pixels from the anti-HA and LAMP1 channels was assessed to determine
internalization of APP into lysosomes (Figure 7B). Representative images are shown in
Figure 7A. Data are shown as mean percent colocalization ± SEM, and quantification
used at least 10 representative cells for each replicate for 4 replicate experiments. Cells in
control plates (26.8 % ± 3.1) were not significantly different from those in cells with
Rac1-DN (34.8 % ± 5.2) or Rac1-CA (31.7 % ± 6.1) mutants. Using a one-way ANOVA
with a post-hoc Tukey test for analysis, these differences are not statistically significant.
These results indicate that transfection of a Rac1 mutant does not affect APP trafficking
to lysosomes in N2A cells.

3.5 Transfection of SN56 cells with Cdc42 mutants does not
affect internalization of APP to lysosomes
To examine the role of Cdc42, SN56 cells were co-transfected with HA-βAPP-CFP,
LAMP1-mCherryFP, and either Cdc42-T17N-GFP, a dominant negative mutant, or
Cdc42-G12V-YFP, a constitutively active mutant. Cells were later surface-labeled with
anti-HA antibodies conjugated to AlexaFluor 647 secondary antibodies, allowed to
internalize for 15 minutes, fixed, and imaged using confocal microscopy. Transfection of
mutants into cells was observed through fluorescence of the YFP- or GFP-tagged
mutants. The co-localization of the brightest 2 % of pixels from the anti-HA and LAMP1
channels was assessed to determine internalization of APP into lysosomes (Figure 8B).
Representative images are shown in Figure 8A. Data are shown as mean percent
colocalization ± SEM, and quantification used at least 10 representative cells for each
replicate for 3 replicate experiments. Cells in control plates (17.9 % ± 2.7) were not
significantly different from those in cells with Cdc42-DN (21.19 % ± 2.721) or Cdc42-
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CA (14.6 % ± 1.1) mutants. Using a one-way ANOVA with a post-hoc Tukey test, for
analysis, these differences are not statistically significant. These results indicate that
transfection of a Cdc42 mutant does not affect APP trafficking to lysosomes in SN56
cells.

3.6 Transfection of N2A cells with Cdc42 mutants does not
affect internalization of APP to lysosomes
The Cdc42 mutants were then examined in N2A cells to observe their effects. Cells were
co-transfected with HA-βAPP-CFP, LAMP1-mCherryFP, and either Cdc42-T17N-GFP,
a dominant negative mutant, or Cdc42-G12V-YFP, a constitutively active mutant. Cells
were later surface-labeled with anti-HA antibodies conjugated to AlexaFluor 647
secondary antibodies, allowed to internalize for 15 minutes, fixed, and imaged using
confocal microscopy. Transfection of mutants into cells was observed through
fluorescence of the YFP- or GFP-tagged mutants. The colocalization of the brightest 2 %
of pixels from the anti-HA and LAMP1 channels was assessed to determine
internalization of APP into lysosomes (Figure 9B). Representative images are shown in
Figure 9A. Data are shown as mean percent colocalization ± SEM, and quantification
used at least 10 representative cells for each replicate for 4 replicate experiments. Cells in
control plates (28.9 % ± 2.7) were not significantly different from those in cells with
Cdc42-DN (38.3 % ± 2.8) or Cdc42-CA (26.9 % ± 4.1) mutants. Using a one-way
ANOVA with a post-hoc Tukey test, for analysis, these differences are not statistically
significant. These results indicate that transfection of a Cdc42 mutant does not affect APP
trafficking to lysosomes in N2A cells.
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Figure 7. Rac1 mutants do not affect APP internalization to lysosomes in N2A cells.
A) N2A cells transfected with HA-βAPP-CFP, Lamp1-chFP (red), and a Rac1 dominant
negative-GFP or a Rac1 constitutively active-GFP mutant, surface-labelled with Zenon647 anti-HA antibodies (green) for 30 minutes, and then fixed or incubated for 15
minutes at 37ºC. After 15 minutes of incubation at 37ºC, colocalization between HAβAPP and Lamp1 was observed. B) Quantification of colocalization analysis between
HA-βAPP and Lamp1 channels with standard error for 15 minute incubations at 37ºC for
control, Rac1-DN, and Rac1-CA from 4 replicate experiments, no significance between
any groups (p<0.05). Scale bar = 5 μm.
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Figure 8. Cdc42 dominant negative and constitutively active mutants do not affect
APP internalization to lysosomes in SN56 cells. A) SN56 cells transfected with HAβAPP-CFP, Lamp1-chFP (red), and a Cdc42 dominant negative-eGFP or a Cdc42
constitutively active-YFP mutant, surface-labelled with Zenon-647 anti-HA antibodies
(green) for 30 minutes, and then fixed or incubated for 15 minutes at 37ºC. After 15
minutes of incubation at 37ºC, colocalization between HA-βAPP and Lamp1 was
observed. B) Quantification of colocalization analysis between HA-βAPP and Lamp1
channels with standard error for 15 minute incubations at 37ºC for control, Cdc42-DN,
and Cdc42-CA from 3 replicates, no significance between any groups (p<0.05). Scale bar
= 5 μm.
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3.7 Inhibition of Rac1, Cdc42, and ROCKII reduces
trafficking of APP to lysosomes in a dose-dependent manner
After transfection of Rac1, Cdc42, and RhoA mutants showed no significant differences
between groups we wanted to verify these results using another method. To do this an
inhibitor for each protein was chosen. The Rac1 inhibitor, EHT 1864, and ROCKII
inhibitor, SR 3677, were chosen due to previous studies showing that their usage was
able to significantly decrease Aβ production in cells (Désiré et al. 2005; Herskowitz et al.
2013).
Furthermore, a ROCKII inhibitor was used because there is currently no commercially
available inhibitor for RhoA. The Cdc42 inhibitor (ML 141) is a novel probe not used in
many studies, but showing high specificity for Cdc42 GTPase (Surviladze et al. 2010).
N2A cells were co-transfected with HA-βAPP-CFP, and LAMP1-mCherryFP. After
transfection and differentiation, cells were incubated in 0.1 % DMSO as a vehicle control
for 18 h, EHT 1864 for 18 h, ML 141 for 1 h, SR 3677 for 6 h, or serum-free medium for
18 h. Each incubation was also divided into 3 concentrations to determine dosedependency based upon concentrations used in previous studies. Incubation times were
also based on studies that used them previously (Désiré et al. 2005; Herskowitz et al.
2013; Hong et al. 2013). Afterwards cells were immediately surface-labeled with antiHA antibodies conjugated to AlexaFluor 647 secondary antibodies, allowed to undergo
protein internalization for 15 minutes, fixed, and imaged using confocal microscopy. The
co-localization of pixels from the anti-HA and LAMP1 channels was assessed to
determine internalization of APP into lysosomes for each inhibitor and concentration
(Figure 10B; Figure 11B; Figure 12B). Representative images are shown in Figure 10A
for EHT 1864, Figure 11A for ML 141, and Figure 12A for SR 3677. Data are shown as
mean percent colocalization ± SEM, and quantification used at least 15 representative
cells for each replicate for 3 replicate experiments, using a one-way ANOVA and Tukey
post-hoc test for analysis.
Inhibition of Rac1 using EHT 1864 caused a significant decrease in trafficking of APP to
lysosomes after incubation. Both 10 μM (14.4 % ± 2.2) and 20 μM (14.0 % ± 1.5)
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Figure 9. Cdc42 dominant negative and constitutively active mutants do not affect
APP internalization to lysosomes in N2A cells. A) N2A cells transfected with HAβAPP-CFP, Lamp1-chFP (red), and a Cdc42 dominant negative-eGFP or a Cdc42
constitutively active-YFP mutant, surface-labelled with Zenon-647 anti-HA antibodies
(green) for 30 minutes, and then fixed or incubated for 15 minutes at 37ºC. After 15
minutes of incubation at 37ºC, colocalization between HA-βAPP and Lamp1 was
observed. B) Quantification of colocalization analysis between HA-βAPP and Lamp1
channels with standard error for 15 minute incubations at 37ºC for control, Cdc42-DN,
and Cdc42-CA from 4 replicates, no significance between any groups. Scale bar = 5 μm.
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concentrations showed significantly lower colocalization (p<0.05) of APP and lysosomes
at 15 minutes compared to control and 0.1 % DMSO cells. The 5 μM concentration (25.6
% ± 2.4) was not significantly different from either control or 0.1 % DMSO groups, but
was significantly higher than 10 μM and 20 μM concentrations (p<0.05). This finding
suggests that pharmacological inhibition of Rac1 is able to affect APP trafficking to
lysosomes, and in a dose-dependent manner. Data are shown as mean percent
colocalization ± SEM, and quantification used at least 15 representative cells for each
replicate for 3 replicate experiments.
Inhibition of Cdc42 using ML 141 also showed a significant decrease in trafficking of
APP to lysosomes after incubation. Both 10 μM (10.3 % ± 1.4) and 20 μM (7.2 % ± 1.4)
concentrations showed significantly lower colocalization of APP and lysosomes at 15
minutes compared to control and 0.1 % DMSO cells (p<0.05). However, the 5 μM
concentration (19.2 % ± 5.9) was not significantly different from either control and 0.1 %
DMSO groups, or 10 μM and 20 μM concentrations. This finding suggests that
pharmacological inhibition of Cdc42 is able to reduce APP trafficking to lysosomes in a
dose-dependent manner. Data are shown as mean percent colocalization ± SEM, and
quantification used at least 15 representative cells for each replicate for 3 replicate
experiments.
The last inhibitor used, SR 3677 for ROCKII inhibition, inhibited trafficking of APP to
lysosomes after incubation as well. Both 10 μM (15.6 % ± 4.4) and 25 μM (11.8 % ± 0.3)
concentrations showed significantly lower colocalization of APP and lysosomes
compared to 15-minute control and 0.1 % DMSO dishes (p >0.05). Again, the 5 μM
concentration (20.4 % ± 1.6) was not significantly different from either control or 0.1 %
DMSO groups, or 10 μM and 20 μM concentrations. This finding suggests that
pharmacological inhibition of ROCKII, a downstream effector of RhoA, is able to reduce
APP trafficking to lysosomes in a dose-dependent manner. Data are shown as mean
percent colocalization ± SEM, and quantification used at least 15 representative cells for
each replicate for 3 replicate experiments.
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3.8 Inhibition of Rac1, Cdc42, and ROCKII does not affect
trafficking of APP to endosomes
Pharmacological inhibition was able to produce a significant effect on APP trafficking to
lysosomes. In order to determine the specificity of this mechanism we examined the
effects of Rac1, Cdc42, and ROCKII inhibition on the internalization of APP through
classical endocytosis to early endosomes. N2A cells were co-transfected with HA-βAPPCFP, and Rab5-mRFP, a compartment marker for early endosomes. After transfection
and differentiation, cells were incubated in 0.1 % DMSO as a vehicle control, EHT 1864,
ML 141, SR 3677, or serum-free media for 18 h. For this experiment, inhibitor
concentrations were all set at 10 μM because this was the lowest concentration that
showed significant results in each experiment done for lysosomal trafficking, so as to
reduce toxicity to the cells. Incubation time was 18 hours for all treatments to allow
easier monitoring and internalization of cell cultures; at these incubation times no toxic
effects were observed in cells. Cells were then surface-labeled with anti-HA antibodies
conjugated to AlexaFluor 647 secondary antibodies, allowed to internalize for 15
minutes, fixed, and imaged using confocal microscopy. The co-localization of pixels
from the anti-HA and Rab5 channels was assessed to determine internalization of APP
into lysosomes after incubation of each inhibitor (Figure 13B). Representative images are
shown in Figure 13A. Data are shown as mean percent colocalization ± SEM, and
quantification used at least 15 representative cells for each replicate for 3 replicate
experiments, using a one-way ANOVA and Tukey post-hoc test for analysis.
Colocalization analysis results were 21.3 % ± 3.4 (control), 17.5 % ± 0.7 (0.1 % DMSO),
19.0 % ± 2.0 (EHT 1864), 17.3 % ± 0.8 (ML 141), and 21.6 % ± 2.1 (SR 3677). None of
the groups were significantly different from the others. These results show that inhibition
of Rac1, Cdc42, and ROCKII have no effect on APP trafficking through classical
endocytosis, while still affecting lysosomal trafficking of APP showing a highly specific
way to inhibit this form of APP transport. Furthermore, this data helps to establish a
possible pathway for the macropinocytosis of APP downstream of Arf6.
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Figure 10. Internalization of APP is decreased in N2A cells after Rac1 inhibition. A)
N2A cells transfected with HA-βAPP-CFP (cyan), and Lamp1-chFP (red). Cells were
then incubated with EHT 1864 or 0.1% DMSO for 18 hours, and immediately surfacelabelled with Zenon-647 anti-HA antibodies (green) for 30 minutes, then incubated for 15
minutes at 37ºC. After 15 minutes of incubation at 37ºC, colocalization between HAβAPP and Lamp1 was observed. B) Quantification of colocalization analysis between
HA-βAPP and Lamp1 channels with standard error for 15 minute incubations at 37ºC for
control, 0.1% DMSO, and EHT using 5uM, 10uM, and 20uM from 3 replicates,
significant difference from control is denoted by * (p<0.05). Scale bar = 5 μm.
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3.9 siRNA knockdown of Rac1 in SN56 cells decreases
trafficking of APP to lysosomes
A third method was used to examine whether the result from mutant transfection or the
result from pharmacological inhibition was what was truly occurring in vitro, so an
siRNA for Rac1 was chosen. SN56 cells were mock transfected or transfected for 48h
with a Negative Control siRNA, or an siRNA against Rac1 for western blotting at 200
nM, 300 nM, and 400 nM concentrations to determine the lowest concentration with a
significant effect, to reduce cytotoxic effects. After blotting, protein expression was
analyzed after being normalized to α-tubulin expression and expressed relative to the
mock transfection (Figure 14C). Data are shown as mean percent colocalization ± SEM,
and quantification used 3 replicate experiments, using a one-way ANOVA and Tukey
post-hoc test for analysis. Relative expressions of Rac1 were 1.23 ± 0.05 (Negative
Control), 0.86 ± 0.04 (200 nM), 0.94 ± 0.14 (300 nM), and 0.72 ± 0.13 (400 nM).
Relative expressions of Rac1 were significantly different between a Negative Control
siRNA, which has no homology with any other genes, and 400 nM groups (p<0.05).
For internalization experiments SN56 cells were co-transfected with HA-βAPP-CFP,
LAMP1-mCherryFP, and siRNA against Rac1 at a 400 nM concentrations based upon
the previous western blot experiments. A negative control siRNA conjugated to
AlexaFluor 647 was also transfected into every plate at 10 nM except for the mock
transfection plate in order to visualize which cells were transfected with the negative
control. Cells transfected with the negative control were assumed to also be transfected
with the Rac1 siRNA, which is not visible. After transfection and differentiation, cells
were immediately surface-labeled with anti-HA conjugated to AlexaFluor 488, allowed
to internalize for 15 minutes, fixed, and imaged using confocal microscopy. The colocalization of pixels from the anti-HA and LAMP1 channels was assessed to determine
internalization of APP into lysosomes (Figure 14B). Representative images are shown in
Figure 14A. Data are shown as mean percent colocalization ± SEM, and quantification
used at least 15 representative cells for each replicate for 4 replicate experiments, using a
one-way ANOVA and Tukey post-hoc test for analysis. Mock (32.6 % ± 0.5) and
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Figure 11. Internalization in N2A cells is decreased after Cdc42 inhibition. A) N2A
cells transfected with HA-βAPP-CFP (cyan), and Lamp1-chFP (red). Cells were then
incubated with ML 141 or 0.1% DMSO for 1 hour, and immediately surface-labelled
with Zenon-647 anti-HA antibodies (green) for 30 minutes, then incubated for 15 minutes
at 37ºC. After 15 minutes of incubation at 37ºC, colocalization between HA-βAPP and
Lamp1 was observed. B) Quantification of colocalization analysis between HA-βAPP
and Lamp1 channels with standard error for 15 minute incubations at 37ºC for control,
0.1% DMSO, and EHT using 5uM, 10uM, and 20uM from 3 replicates, significant
difference from control is denoted by * (p<0.05). Scale bar = 5 μm.
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Figure 12. Internalization in N2A cells is decreased after ROCKII inhibition. A)
N2A cells transfected with HA-βAPP-CFP (cyan), and Lamp1-chFP (red). Cells were
then incubated with SR3677 or 0.1% DMSO for 6 hours, and immediately surfacelabelled with Zenon-647 anti-HA antibodies (green) for 30 minutes, incubated for 15
minutes at 37ºC. After 15 minutes of incubation at 37ºC, colocalization between HAβAPP and Lamp1 was observed. B) Quantification of colocalization analysis between
HA-βAPP and Lamp1 channels with standard error for 15 minute incubations at 37ºC for
control, 0.1% DMSO, and EHT using 5uM, 10uM, and 25uM from 3 replicates,
significant difference from control is denoted by * (p<0.05). Scale bar = 5 μm.
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negative control dishes (30.7 % ± 0.5) showed no significant differences in APP
trafficking. However, the 400 nM concentration of Rac1 siRNA (16.9 % ± 3.2) showed
significantly lower (p<0.05) APP colocalized with lysosomes. This suggests that siRNA
knockdown through siRNA is able to reduce APP transport to lysosomes.

3.10 Rac1 siRNA was unable to produce knockdown in N2A
cells
N2A cells were mock transfected or transfected for 48h with a Negative Control siRNA,
or an siRNA against Rac1 for western blotting at 200 nM, 300 nM, and 400 nM
concentrations to determine the lowest concentration with a significant effect. After
blotting, protein expression was analyzed after being normalized to α-tubulin expression
and expressed relative to the mock (Figure 15). Data used 2 replicate experiments.
Relative expressions of Rac1 were 1.00 ± 0.09 (Mock), 2.50 ± 1.90 (200 nM), 1.45 ±
0.66 (300 nM), and 1.40 ± 0.47 (400 nM). Using the same Rac1 siRNA as the SN56
cells, a knockdown was unable to be produced in N2A cells. This may have been due to
differences in transfection efficiency between the two cell lines, or differences in the
levels of Rac1 protein expressed between SN56 and N2A cells. In addition, a single base
change in the N2A cells in the region covered by the siRNA could also result in failure of
this specific siRNA.

3.11 siRNA knockdown of Cdc42 in N2A cells decreases
transport of APP to lysosomes
In order to study the effects of siRNA knockdown on Cdc42, N2A cells were mock
transfected or transfected for 48h with a Negative Control siRNA, or an siRNA against
Cdc42 for western blotting at 200 nM, 300 nM, and 400 nM concentrations. After
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Figure 13. Internalization of βAPP into endosomes is unaffected after inhibition of
Rac1, Cdc42, and ROCKII. A) N2A cells transfected with HA-βAPP-CFP, and Rab5mRFP (red). Cells were then incubated with EHT1864, ML141, SR3677, or 0.1% DMSO
for 24 hours, and immediately surface-labelled with Zenon-647 anti-HA antibodies
(green) for 30 minutes, then incubated for 15 minutes at 37ºC. After 15 minutes of
incubation at 37ºC, colocalization between HA-βAPP and Rab5 was observed. B)
Quantification of colocalization analysis between HA-βAPP and Rab5 channels with
standard error for 15 minute incubations at 37ºC for control, 0.1% DMSO, and 10uM
EHT1864, ML141, or SR3677 from 3 replicates, no significance between any of the
groups (p<0.05). Scale bar = 5 μm.
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blotting, protein expression was analyzed after being normalized to α-tubulin expression
and expressed relative to the mock transfection (Figure 16C). Data are shown as mean
percent colocalization ± SEM, and quantification used 3 replicate experiments, using a
two-tailed t-test between each concentration and the mock for analysis. The relative
expressions of Cdc42 were 1.01 ± 0.09 (Mock), 0.32 ± 0.19 (200 nM), 0.30 ± 0.25 (300
nM), and 0.24 ± 0.16 (400 nM). The 200 nM and 400 nM concentrations showed
significantly lower expression of Cdc42 as compared to the mock transfection (p<0.05).
For internalization, N2A cells were co-transfected with HA-βAPP-CFP, LAMP1mCherryFP, and siRNA against Cdc42 at 200 nM based upon the previous western blot
experiments. A negative control siRNA conjugated to AlexaFluor 647 was also
transfected into every plate at 10 nM except for the mock transfection plate in order to
visualize which cells were transfected with the negative control. Cells transfected with
the negative control were assumed to also be transfected with the Cdc42 siRNA, which is
not visible. After transfection and differentiation, cells were immediately surface-labeled
with anti-HA conjugated to AlexaFluor 488, allowed to internalize for 15 minutes, fixed,
and imaged using confocal microscopy. The co-localization of pixels from the anti-HA
and LAMP1 channels was assessed to determine internalization of APP into lysosomes
(Figure 16B). Representative images are shown in Figure 16A. Data are shown as mean
percent colocalization ± SEM, and quantification used at least 15 representative cells for
each replicate for 3 replicate experiments, using a one-way ANOVA and Tukey post-hoc
test for analysis. Colocalizations were 28.1 % ± 0.7 (mock), 29.3 % ± 3.1 (negative
control) and 6.8 % ± 0.7 (200nM). Cdc42 knockdown with an siRNA displayed
significantly lower (p<0.05) APP trafficking to lysosomes. Similar to inhibition of Cdc42
with a pharmacological inhibitor, knockdown of Cdc42 was also able to greatly reduce
the transport of APP to lysosomes.
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3.12 siRNA knockdown of RhoA in N2A cells decreases APP
internalization into lysosomes
The effect of RhoA knockdown was studied using N2A cells and an siRNA against
RhoA. For western blotting, N2A cells were mock transfected or transfected for 48h with
a Negative Control siRNA, or an siRNA against RhoA at 50 nM, 75 nM, and 100 nM
concentrations. After blotting, protein expression was analyzed after being normalized to
α-tubulin expression and expressed relative to the mock (Figure 17C). Data are shown as
mean percent colocalization ± SEM, and quantification used 3 replicate experiments,
using a two-tailed t-test between each concentration and the mock for analysis. The
relative expressions of RhoA were 1.01 ± 0.09 (Mock), 0.31 ± 0.10 (50 nM), 0.47 ± 0.13
(75 nM), and 0.47 ± 0.17 (100 nM). The 50 nM, 75 nM, and 100 nM concentrations all
showed significantly lower expression of RhoA as compared to the mock (p<0.05).
For internalization experiments, N2A cells were co-transfected with HA-βAPP-CFP,
LAMP1-mCherryFP, and siRNA against RhoA at 50 nM based upon the previous
western blot experiments. A negative control siRNA conjugated to AlexaFluor 647 was
also transfected into every plate at 10 nM except for the mock transfection plate in order
to visualize which cells were transfected with the negative control. Cells transfected with
the negative control were assumed to also be transfected with the RhoA siRNA, which is
not visible. After transfection and differentiation, cells were immediately surface-labeled
with anti-HA conjugated to AlexaFluor 647, allowed to internalize for 15 minutes, fixed,
and imaged using confocal microscopy. The co-localization of pixels from the anti-HA
and LAMP1 channels was assessed to determine internalization of APP into lysosomes
(Figure 17B). Representative images are shown in Figure 17A. Data are shown as mean
percent colocalization ± SEM, and quantification used at least 15 representative cells for
each replicate for 3 replicate experiments, using a one-way ANOVA and Tukey post-hoc
test for analysis. Colocalizations were 28.1 % ± 0.7 (mock), 29.3 % ± 3.1 (negative
control) and 9.3 % ± 2.1 (50nM). RhoA knockdown presented significantly lower
(p<0.05) APP trafficking to lysosomes. RhoA knockdown, like inhibition previously, was
able to significantly reduce the transport of APP to lysosomes.
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Figure 14.

Internalization of βAPP into lysosomes is decreased by siRNA

knockdown of Rac1. A) SN56 cells transfected with HA-βAPP-CFP, Lamp1-chFP (red),
a Rac1 siRNA (MSS237709), and Stealth RNAi siRNA Negative Control Med GCAlexaFluor 647 for 48 hours. Cells were then differentiated for a day and then
immediately surface-labelled with Zenon-488 anti-HA antibodies (green) for 30 minutes,
then incubated for 15 minutes at 37 ºC. After 15 minutes of incubation at 37 ºC,
colocalization between HA-βAPP and LAMP1 was observed. B) Quantification of
colocalization analysis between HA-βAPP and Lamp1 channels with SEM for 15 minute
incubations at 37 ºC for mock transfection, negative control, and rac1 siRNA. C) Western
blot image and quantification with a mock, negative control, or 200 nM, 300 nM, or 400
nM concentrations of Rac1 siRNA. Data retrieved from 3 replicates for Western Blots
and 4 replicates for internalization, significance is denoted by * (p < 0.05). Scale bar = 5
μm.
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Figure 15.

Rac1 siRNA did not induce knockdown in N2A cells. N2A cells

transfected with HA-βAPP-CFP, Lamp1-chFP (red), a Rac1 siRNA (MSS237709) for 48
hours. Cells were then differentiated for a day before protein extraction. Western blot
image from a mock transfection, negative control siRNA, 200 nM, 300 nM, or 400 nM
concentrations of Rac1 siRNA. Data is from 2 replicates.
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3.13 Pharmacological inhibition of Rac1, Cdc42, and ROCKII
show significantly reduced secretion of Aβ40
After showing through siRNA knockdown and pharmacological inhibition of Rac1,
Cdc42, and RhoA that lysosomal but not endosomal trafficking of APP could be reduced
we had to look ahead towards the larger picture. We needed to see whether our observed
decreases in APP transport translated to actual decreases in Aβ production. The first Aβ
peptide studied was Aβ40 because Aβ40 is generated in larger amounts and we wanted to
see whether effects could be observed in its production before moving to Aβ42. A
Human Aβ40 ELISA kit (Invitrogen) was used to analyze cell culture media after
pharmacological inhibition. N2A cells were transfected with HA-βAPP-CFP and then
differentiated. After differentiation cells were incubated with a 0.1 % DMSO vehicle
control, or inhibitors at 10 μM for Rac1 (EHT 1864), Cdc42 (ML 141), or ROCKII (SR
3677) for 24h. This incubation time was chosen to reduce possible cytotoxic effects from
incubating for too long while ensuring that there could be enough Aβ40 produced to be
detectable. After incubation, cell media were extracted and analyzed. Cell media was
analyzed in the ELISA as Aβ is known to be secreted by cells into surrounding fluid,
allowing measurement of Aβ produced (Walsh et al. 2002). Experiments were performed
with 3 replicates, and data shown represents the mean ± SEM normalized to the vehicle
control, analyzed using a one-tailed t-test. Production of Aβ40 after inhibition of Rac1
(56.2 % ± 6.4), Cdc42 (49.3 % ± 17.7), and ROCKII (38.3 % ± 14.8) are all significantly
lower than control (110.5 % ± 20.7) (p<0.05) (Figure 18).

3.14 Pharmacological inhibition of Rac1, Cdc42, and ROCKII
also shows reduced secretion of Aβ42
The next step after analyzing production of Aβ40 was to look at Aβ42. This is necessary
to study along with Aβ40 as Aβ42 is the more toxic of the two peptides, and it has been
strongly suggested that the ratio between the two may be a key factor in the development
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Figure 16.

siRNA knockdown of Cdc42 decreases internalization of APP to

lysosomes. A) N2A cells transfected with HA-βAPP-CFP, Lamp1-chFP (red), a Cdc42
siRNA (MSS247082), and Stealth RNAi siRNA Negative Control Med GC-AlexaFluor
647 for 48 hours. Cells were then differentiated for a day and then immediately surfacelabelled with Zenon-488 anti-HA antibodies (green) for 30 minutes, then incubated for 15
minutes at 37 ºC. After 15 minutes of incubation at 37 ºC, colocalization between HAβAPP and LAMP1 was observed. B) Quantification of colocalization analysis between
HA-βAPP and Lamp1 channels with standard error for 15 minute incubations at 37 ºC for
mock transfection, negative control, and Cdc42 siRNA. C) Western blot image and
quantification with a mock, negative control, or 200 nM, 300 nM, or 400 nM
concentrations of Cdc42 siRNA. Data retrieved from 3 replicates for Western Blots and 3
replicates for internalization, significance is denoted by * (p < 0.05). Scale bar = 5 μm.
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Figure 17.

siRNA knockdown of RhoA decreases internalization of APP to

lysosomes. A) N2A cells transfected with HA-βAPP-CFP, Lamp1-chFP (red), a RhoA
siRNA (s119551), and Stealth RNAi siRNA Negative Control Med GC-AlexaFluor 647
for 48 hours. Cells were then differentiated for a day and then immediately surfacelabelled with Zenon-488 anti-HA antibodies (green) for 30 minutes, then incubated for 15
minutes at 37 ºC. After 15 minutes of incubation at 37 ºC, colocalization between HAβAPP and LAMP1 was observed. B) Quantification of colocalization analysis between
HA-βAPP and Lamp1 channels with standard error for 15 minute incubations at 37 ºC for
mock transfection, negative control, and RhoA siRNA. C) Western blot image and
quantification with a mock, negative control, or 50 nM, 75 nM, or 100 nM concentrations
of RhoA siRNA. Data retrieved from 3 replicates for Western Blots and 3 replicates for
internalization, significance is denoted by * (p < 0.05). Scale bar = 5 μm.
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and progression of Alzheimer’s (Iijima et al. 2008; Wiltfang et al. 2007). A Human Aβ42
ELISA kit (Invitrogen) was used to analyze cell culture media after pharmacological
inhibition. N2A cells were transfected with HA-βAPP-CFP and then differentiated. After
differentiation cells were incubated with a 0.1 % DMSO vehicle control, or inhibitors at
10 μM for Rac1 (EHT 1864), Cdc42 (ML 141), or ROCKII (SR 3677) for 48h. This
longer incubation time compared to the Aβ40 experiments was used since cells produce
so little Aβ42 as compared to Aβ40. After incubation, cell media was extracted and
analyzed. Experiments were performed with 3 replicates, and data shown represents the
mean ± SEM normalized to the vehicle control, analyzed using a one-tailed t-test.
Production of Aβ42 after inhibition of Rac1 (56.5 % ± 9.3), Cdc42 (48.6 % ± 8.0), and
ROCKII (41.4 % ± 5.8) were all significantly lower (p<0.05) than control (109.6% ± 4.8)
(Figure 19). These results show that not only could pharmacological inhibition reduce
Aβ40 production, but also Aβ42 production as well. Taking our results a step further, we
divided the mean of the normalized Aβ42 from the mean of the normalized Aβ40, for
each treatment, to examine the ratio of Aβ42 to Aβ40 production. The Aβ42/Aβ40 ratio
after inhibition of Rac1, Cdc42, and ROCKII remained unchanged compared to control
(essentially 1.0).
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Aβ40 production is reduced after inhibition of Rac1, Cdc42, and

ROCKII. A) N2A cells transfected with HA-βAPP-CFP for 24h then differentiated for
24h. Differentiation medium was then replaced with fresh media containing 0.1%
DMSO, EHT1864 (Rac1 inhibitor), ML141 (Cdc42 inhibitor), or SR3677 (ROCKII
inhibitor) for 24 hours. Immediately afterwards media samples were frozen and later
analyzed using an Invitrogen Aβ40 ELISA according to manufacturer instructions. Data
retrieved from 3 replicates, significance is denoted by * (p<0.05).
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Aβ42 production is reduced after inhibition of Rac1, Cdc42, and

ROCKII. A) N2A cells transfected with HA-βAPP-CFP for 24h then differentiated for
24h. Differentiation media was then replaced with fresh medium containing 0.1%
DMSO, EHT1864 (Rac1 inhibitor), ML141 (Cdc42 inhibitor), or SR3677 (ROCKII
inhibitor) for 24 hours. Immediately afterwards media samples were frozen and later
analyzed using an Invitrogen Aβ42 ELISA according to manufacturer instructions. Data
retrieved from 3 replicates, significance is denoted by * (p<0.05).
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Chapter 4: Discussion

Our laboratory has previously indicated that lysosomes may be significantly involved in
the processing of APP (Pasternak et al. 2003), and that this process occurs through a
rapid internalization of APP from the cell surface (Lorenzen et al. 2010). Furthermore,
this process is mediated by the Arf6-GTPase, and may work through macropinocytosis
(Tang et al. 2015). The purpose of this study was to identify possible effectors
downstream of Arf6 to explore the pathway through which this APP trafficking
mechanism occurs and also to see if inhibition or knockdown of these effectors could
produce a molecular result visible through microscopy, which could carry through to
changes in Aβ production. Through the use of fluorescently-labeled cell surface APP and
compartment markers we were able to observe the trafficking of APP into both
lysosomes and endosomes, following both our novel pathway and the classical pathway
for APP transport in SN56 and N2A cells.
Using transfection of dominant negative and constitutively active mutants for Rac1,
Cdc42, and RhoA we were unable to show any significant changes in APP transport to
lysosomes. It is not clear why these constructs did not work in these cell lines. It is
possible that the amount of mutant protein transfected into our cell lines was not enough
to offset the normal function of endogenously produced Rac1, Cdc42, or RhoA. We
verified that these constructs were transfected by imaging (they all had fluorescent tags),
however the intensity of the fluorescent channel delineating the mutant proteins is not
necessarily indicative of a noticeable effect. Additionally, though similar constructs have
been shown to function in other cell types, it is possible that our mutant proteins are nonfunctional in N2A cells, for example if they do not interact properly with their required
interaction partners in neuronal cells. Nevertheless, we showed that pharmacological
inhibition of Rac1, Cdc42, and ROCKII could significantly reduce the amount of APP
being transported to lysosomes. Furthermore, this reduced transport translated into
significantly reduced levels of both Aβ40 and Aβ42 production, reinforcing a connection
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between our proposed pathway and the endpoint of APP processing. While we observed
none of these differences in APP trafficking to lysosomes using dominant and
constitutively active mutants we were able to show significant changes through the use of
siRNA knockdowns. In SN56 cells a Rac1 siRNA was able to elicit a significant decrease
in APP transport to lysosomes, similar to the decrease observed using inhibitors. In N2A
cells the same Rac1 siRNA was not able to produce a knockdown, possibly due to
differences in protein expression or differences in siRNA transfection efficiency,
however both Cdc42 siRNA and RhoA siRNAs were able to exhibit a decrease in APP
transport to lysosomes, similar to their inhibitor counterparts.

4.1 Internalization of APP from the cell surface can be
regulated through Rac1, Cdc42, and RhoA
Based upon a previous study in our lab that implicated Arf6 in the regulation of APP
transport to lysosomes by macropinocytosis, a number of small GTPases were chosen for
study. These GTPases have all been previously thought to be part of or necessary for
macropinocytosis to occur and have all been suggested to interact downstream of Arf6 in
the literature, except for Cdc42. Based upon the internalization experiments performed to
observe APP transport, we observed results with Rac1, Cdc42 and RhoA that were highly
similar to those that found previously with Arf6 (Tang et al. 2015).
Of the three Rho GTPases above, Rac1-GTPase is most strongly tied to macropinosome
formation. Rac1 is essential for membrane ruffling, and eventually macropinosome
formation, in a large number of cell types including macrophages and epithelial cells,
requiring both activation and then deactivation of the GTPase for proper function (Fujii et
al. 2013). Furthermore, it has been shown that ARNO, a guanine nucleotide exchange
factor for Arf GTPases, activity leads to the activation of endogenous Arf6, and this
activation leads to increased Rac1 activation. Perhaps more importantly, it was recently
shown that an adaptor protein that binds APP, FE65, stimulates both Arf6 activation as
well as Rac1 activation (Cheung et al. 2014). In this study Chinese hamster ovary (CHO)
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cells were transfected to overexpress FE65 or transfected with an siRNA for FE65
knockdown, showing an increase or decrease respectively in Rac1 activity. This study
also demonstrated that cells overexpressing FE65, but with Arf6 knocked down, were
unable to activate Rac1, showing that Rac1 is downstream of Arf6 which is ultimately
regulated by FE65. Taken together with the data in our study, this strongly suggests that
APP may bind FE65, stimulating Arf6 activity, and further induce Rac1-mediated
membrane ruffling for the endocytosis of APP. Our lab has also observed that mutation
of tyrosine at the FE65 binding site was able to inhibit macropinocytosis, further
implicating FE65 as a major player upstream of both Rac1 and Arf6 in the
macropinocytosis of APP (unpublished results).
Cdc42, like Rac1, has been heavily implicated in the formation of macropinosomes,
especially regarding its effects on actin polymerization and reorganization. Cdc42 has
been shown to bind neural-Wiskott-Aldrich syndrome protein (N-WASP), which binds
and then activates the Arp 2/3 complex (Matas et al. 2004; D’Souza-Schorey et al. 2006).
This results in polymerization of an actin filament, forcing the plasma membrane out into
a membrane ruffle and eventually macropinosome formation (Kerr et al. 2009).
Furthermore, Cdc42-mediated N-WASP function requires binding of the Abi1, an
essential component of the WAVE protein complex that is activated by Rac (Innocenti et
al. 2005). It has also been shown that Cdc42 is likely downstream of Arf6 and that Arf6
activity may regulate Cdc42 activation and its effects on membrane dynamics and cell
migration (Osmani et al. 2010; Jayaram et al. 2011). Taken together with our current
data, the idea that Cdc42 acts downstream of Arf6 in our pathway for internalization of
APP is reinforced. Additionally, the Cdc42-activated actin polymerization needed for
macropinosome formation seems to be regulated by Rac1 helping to elucidate what role
Rac1 may have in our suggested pathway.
RhoA has been shown to be an essential regulator of neuronal morphology, often with
effects opposing Rac1. Often Rho upregulates apoptotic pathways, whereas Rac
upregulates pathways for growth (Stankiewicz et al. 2014), requiring a balance between
the two to maintain neuronal health, especially in dendritic growth (Newey et al. 2005).
While not many studies have observed the effects of RhoA or any of the other Rho
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subfamily GTPases a few have shown the presence of RhoA activity at the ruffles of
membranes and in macropinosomes (Zawistowski et al. 2013; Pertz et al. 2006).
Furthermore, RhoA localizes to the cell membrane unlike other Rho subfamily GTPases
(Stankiewicz et al. 2014). While our data shows that knockdown or inhibition of RhoA
has similar effects to Rac1 and Cdc42, it is possible that RhoA may be required for
macropinocytosis to complete. As discussed above, Rac1 activation and then subsequent
deactivation is required for macropinosome closure and maturation (Fujii et al. 2013).
Similarly, RhoA activation and deactivation may be required for full macropinosome
closer and maturation as well in a manner opposite to that of Rac1. This is supported
through a study that shows that Arf6 activates Rac1 and Arf6 in opposite manners to
regulate spine formation in neurons (Kim et al. 2015) and another study showing that
ROCK2, a downstream effector of RhoA, attenuates Rac1 activity at the leading edge of
lamellipodia and membrane ruffles (Newell-Litwa et al. 2015). In the same study,
ROCK2 was also shown to activate cofilin, a protein that mediates actin
depolymerization.

4.2 Building a pathway downstream of Arf6
Altogether the three Rho GTPases above appear to all be downstream of Arf6 and
necessary for the regulation of actin dynamics and macropinosome formation. A
proposed pathway visualizing the placement of just Arf6, Rac1, Cdc42, and RhoA
(Figure 20) would place APP’s binding to adaptor FE65 at the top, which is then able to
bind to Arf6 (Cheung et al. 2015). Arf6 would then be able to activate Rac1 through
some currently unknown mechanism, as well as possible being able to activate Cdc42.
Rac1, through the WAVE protein complex would be able to bind and activate the Arp 2/3
complex and promote membrane ruffling through actin polymerization (Innocenti et al.
2005). Rac1, through binding the WAVE complex would allow the Abi1 protein complex
to activate N-WASP, allowing Cdc42 to bind to N-WASP. The binding of Cdc42 and NWASP would also activate the Arp 2/3 complex and further promote actin polymerization
and membrane ruffling. As the macropinosome forms and matures, Rac1 and Cdc42
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Figure 20. Proposed initial model for Arf6-mediated macropinocytosis of APP. Area
in red represents the portion of this pathway focused on in this study. APP binding to
FE65 activates Arf6, upregulating Cdc42, Rac1, and RhoA. Cdc42 and Rac1 activate the
N-WASP and WAVE complexes, respectively. The WAVE complex is required to
activate N-WASP. Both complexes bind and activate the Arp2/3 complex and initiate
actin polymerization and membrane ruffling, leading to formation of a macropinosome.
RhoA is activated at a delayed time, upregulating ROCK2 which attenuates Rac1 and
activates cofilin. Cofilin and the attenuation of Rac1 lead to actin depolymerization and
the eventual maturation and fission of the macropinosome from the membrane.
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would need to be downregulated, while Arf6 upregulates RhoA simultaneously. RhoA
would upregulate ROCKII, attenuating Rac1 and activating cofilin allowing the
macropinosome to further mature and undergo fission from the cell membrane (NewellLitwa et al. 2015).

4.3 Inhibition of APP Trafficking to Lysosomes Decreases in
Production of Aβ40 and Aβ42
After observing significant decreases in the trafficking of APP to lysosomes with
inhibition and knockdown of Rac1, Cdc42, and RhoA we wanted to know if these results
would translate into observable differences in Aβ production. Of the two common Aβ
peptides, Aβ42 is considered to be more toxic (Iijima 2008; Kumar-Singh 2006). However, it
has been suggested that not only is the absolute concentration of Aβ42 important but also the
ratio of Aβ42 to Aβ40 as well (Yin 2007). Furthermore, it has been shown previously that
Aβ40 may have a neuroprotective effect against Aβ42 (Kumar-Singh 2006; Murray 2009).
These studies suggest that Aβ40 may actually inhibit Aβ42 oligomerization or upregulate
sequestration of Aβ42 leading to increased clearance.

After analysis of our cells incubated with Rac1, Cdc42, and ROCK2 inhibitors it was
revealed that inhibition of these three proteins was able to reduce Aβ40 and Aβ42
production. Furthermore, production was decreased by the same amount for both
peptides. First, this shows that changes in APP transport are able to translate show a
measured decrease in Aβ production. Although the Aβ42/Aβ40 ratio did not change
significantly, the absolute concentration of Aβ42 in the medium was still decreased,
supporting the hypothesis that Aβ can be produced in the lysosome. Secondly, the role of
Rac1, Cdc42, and ROCK2 is further reinforced in our novel pathway, as their inhibition
was able to demonstrate a result similar to Arf6 in one of our previous studies (Tang et al.
2015). Inhibition of Rac1 showing a decrease Aβ production has been observed
previously using EHT 1864, with similar results for Aβ42 and Aβ40 production (Désiré
et al. 2005). Similarly, Aβ production has been previously shown to be decreased with
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ROCK2 inhibition with a similar result (Herskowitz et al. 2013). While both these studies
were the source of the incubation times and concentrations that we used, neither of these
studies identified a mechanism for reduction of Aβ production. Our results extend the
observations that these inhibitors reduce APP trafficking by macropinocytosis to
lysosomes and provide the mechanism for the observed Aβ reduction, as well as
providing support for the future use of these inhibitors in AD therapy. However, the
previous study from Herskowitz et al (2013) also visualized APP after incubation of the
SR 3677 inhibitor. While we observed a decrease in APP transport to lysosomes that
resulted in decreased Aβ production, their group observed an increase in BACE1 and
APP to lysosomes after 6 h incubation. However, their study simply looked at all APP at
the time of fixation. Our study observed only the movement cell surface-labelled APP
into lysosomes after incubation; therefore, our study visualizes the trafficking of APP,
whereas the study by Herskowitz et al is really only looking at APP localization rather
than trafficking. Furthermore, it is stated by Désiré et al that the increased colocalization
of BACE1 and APP with lysosomes was likely what lead to the decrease in Aβ
production, but the mechanism through which this might occur is unclear. It is also
possible that the concentration they used for ROCK2 inhibition was too high resulting in
off-target effects. The concentration used was 50 μM, a 5-fold increase higher than the
concentration used in ours, and SR 3677 is able to inhibit ROCK1 as well at high enough
concentrations, with an IC50 10-fold higher than that of ROCK2.

4.4 Current and Future Studies for Alzheimer’s Disease
Therapy
Much research is based around the Amyloid Cascade Hypothesis, with the overall goal of
reducing Aβ production. Currently, many studies seek to inhibit the pathway directly
through regulation of each step of the APP processing pathway. Some studies look at γsecretase to inhibit the final γ-cleavage that produces Aβ42 (Yin et al. 2007; Ling et al.
2015). However, PS1 has been shown to be required for proper neuronal development, so
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the end results of inhibition of the γ-secretase are questionable (Shen et al. 1997). Other
studies look at BACE1 inhibition, in order to stop the initial cleavage (Strömberg et al.
2015). Similar to studies looking to regulate γ-cleavage, studies looking to inhibit
BACE1 may run into difficulty as BACE knockout mice exhibit significant neurological
changes and BACE1 is involved in many functions such as axon growth, synapse
function, and muscle spindle maintenance (Vassar et al. 2014). However, there are a
number of BACE1 inhibitors currently in different phases of clinical trials (Vassar 2014).
Another strategy for treatment of AD which has fallen into disfavour is the use of
compounds meant to bind Aβ. This treatment was based upon the idea that aggregation of
Aβ was what leads to cytotoxicity and neuronal death, however so far none have shown
any positive results (Golde et al. 2011). As a result of these difficulties and previous
failures, a promising avenue for research is soluble Aβ fragments referred to as Amyloid
Derived Diffusible Ligands (ADDLs), which have shown to be extremely toxic to
neurons as well as correlating with synaptic loss, which is one of the most important
factors in the progression of Alzheimer’s (Tam et al. 2012). Additionally, Soluble Aβ
levels have been shown to correlate better with cognitive dysfunction much more closely
than the appearance of plaques (Tomic et al. 2009).
Our findings provide a new method to regulate Aβ production by reducing APP transport
to lysosomes, as well as outlining a number of new proteins to study further for therapy
in Alzheimer’s disease. While Rac1, RhoA, and Cdc42 have been strongly shown to be
necessary for this the functioning of this pathway we still have little understanding how
everything fits together. Although an intricate pathway has been proposed above (Figure
20) each step within the pathway needs to be verified if we are to truly understand the
whole mechanism. Beginning with inhibition or knockdown of the FE65 adapter protein
we should verify whether we are able to produce results similar to the internalization
experiments shown in this study and our original Arf6 experiments. Although FE65 is
what binds and activates Arf6, meaning it is upstream of Arf6 activation, it requires
binding of the original APP molecule to FE65 in order to initiate the pathway cascade. If
we are able to inhibit APP transport to lysosomes and therefore Aβ production at this first
binding step, then we would be able to very specifically inhibit Aβ production without
affecting normal cell physiology that requires the use of Arf6 or any of its downstream
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effectors. However, it has also been shown previously in animal models that while single
knockout models of FE65 family proteins appear normal, double knockout mice, for
FE65 and FE65-like 1 (FE65L1), exhibit significant neurodevelopmental defects
(McLoughlin et al. 2008). This points to some redundancy in the FE65 family of
proteins, but still shows that they, and by extension APP processing, are extremely
important to neuronal development. Therefore, it is also necessary to explore and validate
the rest of the pathway to look for another therapeutic target. This can be done by run
activation assays for phosphorylated GTPases after knockdown or inhibition of upstream
effectors. For example, in order to verify that our pathway requires Arf6-activation in
order for downstream RhoA upregulation, we can compare levels of phosphorylated
RhoA with a control and an Arf6 knockdown. From this experiment we might expect a
decreased level of phosphorylated RhoA with an Arf6 knockdown. Additionally, we
could knockdown Arf6 for example, while transfecting a constitutively active mutant for
Rac1 in order to see if we could rescue some of the observed attenuation of APP transport
to lysosomes. This could help tease out which proteins in the pathway are really upstream
or downstream from others, as it is entirely possible that the GTPases examined in this
study work at the same time as and not downstream of Arf6. In addition, the functionality
of the Rac1, Cdc42, and RhoA mutants should be examined following the negative
results outlined above. An experiment that could be performed for mutant functionality
could look at phalloidin conjugate stains for actin filaments after transfection with the
dominant negative and constitutively active constructs to observe their effects on actin
dynamics and ruffle formation. We must also further verify whether Rac1, Cdc42, and
RhoA affect our pathway through regulation of macropinocytosis. This could also be
determined through the staining of actin filaments with phalloidin conjugates to visualize
effects of inhibition of formation of membrane ruffles (Boshans et al. 2000), or through
the visualization of macropinosomal markers such as SNX5 (Kerr et al. 2006). However,
markers of macropinosomes such as SNX5 also localize to endosomes as well making
differentiation between the two compartments difficult (Merino-Trigo et al. 2004).
Furthermore, we should examine whether our results regarding APP transport and Aβ
production can translate into neurons and mice for future clinical applications. In
particular, SR3677 has already been used previously in mice with stereotaxic injections
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with a similar decrease in Aβ production (Herskowitz et al. 2013). Similarly, EHT1864
has been shown to demonstrate decreases in Aβ production in guinea pigs (Désiré et al.
2005). However, further application of these inhibitors such as for clinical studies are will
need to be performed.

4.5 Conclusions
This study provides the foundation for further study of an FE65-mediated pathway that
results in the endocytosis of APP to lysosomes. Our lab previously identified a novel and
direct pathway for the transport of APP to lysosomes, a possible production site for Aβ.
This was expanded further to identify Arf6 as a possible candidate for the initiation of the
endocytosis of APP through a macropinosome-like pathway. This was reinforced through
observation that an Arf6 knockdown also exhibited reduced Aβ production. Our current
study further demonstrates that the Rho GTPases, Rac1, Cdc42, and RhoA, were able to
demonstrate results comparable to those previously observed with Arf6. All three
GTPases

showed

decrease

trafficking

of

cell-surface

labeled

APP

through

pharmacological inhibition as well as small interfering RNA knockdown. These results
are supported by previous studies that indicate that Rac1, Cdc42, and RhoA are all
downstream effectors of Arf6. A possible model for this pathway is also proposed where
FE65 may bind APP, leading to the activation of Arf6. Arf6 would then activate Rac1
and Cdc42, which promote membrane ruffling and macropinosome formation. RhoA
would also be activated at a later time leading to actin depolymerization and
macropinosome maturation. The macropinosome would then undergo fission from the
cell membrane, and later fuse with a lysosome, transporting APP to its site of production.
Additionally, using inhibitors for the above GTPases we were also able to observe
significant decreases in both Aβ40 and Aβ42 production. These results have been
observed previously, however other studies have never connected observable changes in
APP transport from the cell surface to lysosomes with these proteins to changes in Aβ
production as we have here. Further work should be done to further examine each step of
this pathway starting from APP binding to FE65, and then moving down the pathway
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looking for a target for therapy that is specific enough to inhibit this pathway while
leaving other important pathways intact. Hopefully these results will be able to further
our understanding of APP trafficking in Alzheimer’s disease and promote the discovery
of a cure in the future for this disease.
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